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Abstract
ERICKA LASHONDA SMITH. Non-canonical PI3’Kinase Signaling Regulates
AKT3 Activity in PTEN-null Basal Breast Cancer Cell Lines. (Under the direction
of STEPHEN PAUL ETHIER).
A subset of basal breast cancer patients has tumors overexpressing EGFR, loss
of PTEN expression and mutated p53; these alterations cooperate and result in a
poor prognosis for these patients. PTEN is a direct negative regulator of PI3’Kinase
enzymatic activity and loss of PTEN expression is correlated with elevated
PI3’Kinase pathway activation. In the presented dissertation, we utilized a panel of
PTEN-null basal breast cancer cell lines containing constitutive AKT activation and
elevated levels of EGFR to model this subset of breast cancer patients. We first
investigated the response of AKT phosphorylation to PTEN re-expression in the
cell line panel. We found that PTEN re-expression failed to reverse the constitutive
AKT activation present in the HCC-38, SUM-149 and MDA-MB-436 cells;
therefore, we used pharmacological inhibitors of PI3’Kinase pathway mediators to
inhibit AKT phosphorylation. We found that pan class I PI3’Kinase inhibition
(BKM120) and pan mTOR inhibition (KU0063794) failed to ablate AKT
phosphorylation in most of the cells within the panel. Furthermore, we found that
the SUM-149 and MDA-MB-436 cell lines were resistant to the allosteric AKT
inhibitor, MK2206, which led to the observation that these cells harbor elevated
levels of AKT3 gene and protein expression. shRNA mediated knockdown of AKT3
revealed that AKT3 was contributing to the resistance of AKT phosphorylation in
the

SUM-149

cells

to

inhibition

of

PI3’Kinase

pathway

mediators.

Immunoprecipitation of AKT1 and AKT3 after treatment of the SUM-149, MDAxvii

MB-436 and HCC-1937 cell lines with inhibitors of PI3’Kinase pathway mediators
and PI3’Kianse isoform specific inhibitors, revealed that AKT1 phosphorylation is
regulated by canonical PI3’Kinase signaling mechanism and that AKT3 is
regulated by non-canonical PI3’Kinase signaling, with emphasis on the class II
PI3’Kinases as playing an important role in this regulation. In addition, we
demonstrate that PTEN re-expression in PTEN-null basal breast cancer cell lines
results in restoration of canonical PI3’Kinase signaling as the primary driver of AKT
activation. We conclude that non-canonical PI3’Kinase signaling is activated in
PTEN null basal breast cancer cells expressing AKT3, and that this regulation can
be reverted to canonical signaling by restoration of PTEN activity.

xviii

Chapter 1:
Literature Review
Breast cancer statistics
In 2018, it is expected that there will be 330,080 newly diagnosed cases of
invasive and non-invasive breast cancer and 40,920 breast cancer-related deaths
in the United States. Breast cancer is the second-most commonly diagnosed
cancer in women with a probability of 1 in 8 women developing breast cancer
during her lifetime (Siegel Rebecca et al., 2018).
Breast cancer arises when the cells in the breast develop genetic
abnormalities resulting in unchecked cellular growth and other physiological
adaptations resulting in tumorigenesis (Hanahan and Weinberg, 2000). These
adaptations include sustaining proliferative signaling, evading growth suppressors,
resisting cell death, enabling replicative immortality, inducing angiogenesis, and
activating invasion and metastasis and are known collectively as the hallmarks of
cancer (Hanahan and Weinberg, 2000).

Breast cancers can be broadly

categorized into two groups: non-invasive and invasive. Non-invasive cancers
remain in a particular region of the breast, without spreading to surrounding
tissues. Invasive breast cancers spread beyond the breast to other parts of the
body through the bloodstream and lymph nodes. Invasive breast cancers are
commonly classified as invasive ductal carcinoma or invasive lobular carcinoma,
and arise from the cells of the terminal duct lobular unit (Sainsbury et al., 1994;
1

Wellings et al., 1975a). Despite the nomenclature, the lobular and tubular
carcinomas are thus named due to their cellular morphology and not for the
structure in which these cells arise; however, the clinical implication of these
cancers arise from the prevalence of each type (Domagala et al., 1993; Wellings
et al., 1975b). Invasive ductal carcinomas are the most common type of breast
cancer identified, and this morphology encompasses 70-80% of breast tumors
presented in the clinic, while invasive lobular carcinomas account for
approximately 10-15% of breast tumors (Arps et al., 2013). It is important to note
that sarcomas and lymphomas are other less-common forms of breast cancer,
arising from connective tissue and lymph tissue, respectively. Most women
diagnosed with breast cancer have no family history of breast cancer; women with
heritable genetic mutations associated with breast make up only 5-10% of the total
breast cancer patient population (Siegel Rebecca et al., 2018). Risk factors for
developing breast cancer include, but are not limited to: being female, being
overweight, menarche younger than 12, alcohol use, and menopause at an earlier
age (Theodoratou et al., 2017).
Clinical Classification of breast cancer
Breast cancer is clinically classified by the presence of the estrogen
receptor (ER), progesterone receptor (PR) or the human epidermal growth factor
receptor 2 (HER2) (Donegan William, 1997). Patients lacking expression of ER,
PR, and HER2 are classified as triple negative breast cancer (TNBC) (Dent et al.,
2007; Podo et al., 2010b). The expression of ER, PR and HER2 are important
2

clinical features because it allows oncologists to design rational treatment options
based upon the individual or combination expression of these proteins.

The

presence of ER, PR and HER2 can serve as predictive biomarkers that allow
oncologists to determine the probability that a patient will achieve a response to
targeted treatment based upon receptor expression, or they can serve as
prognostic biomarkers that allow clinicians to predict the probability of disease
recurrence, disease progression and patient survival.
ER and PR belong to the nuclear receptor family of proteins, which are
unique due to their ability to directly interact with DNA sequences and function as
transcription factors (Farooq, 2015; Williams and Sigler, 1998). Ligands for ER
and PR can be endogenous steroid and non-steroidal hormones, although
exogenous hormones can also bind to these hormone receptors (Farooq, 2015).
Patients with tumor samples considered positive for the presence of ER, PR or
both are treated with hormone therapy and tend to have a favorable response to
therapy.

3

HER2 positive breast cancer
HER2 gene amplification and subsequent overexpression occurs in 15-20%
of invasive breast cancers; overexpression of HER2 can be up to 100-fold higher
in tumor cells compared to expression of HER2 in normal tissue (Cheang et al.,
2009; Gutierrez and Schiff, 2011; Moasser, 2007). Immunohistochemical (IHC)
staining of HER2 is used
to determine a “score”
for

HER2

based

positivity,

not

upon

presence of HER2 (as
HER2

expression

is

found in normal breast
tissue), but based upon
the intensity of HER2
staining and membrane Figure 1.1: HER2+ staining guidelines: IHC images of human
localization.

breast tumor samples stained with the D8F12 antibody. Image
Figure 1.1 adapted from Ross et al. (Rao et al., 2013; Ross et al., 2003)

shows the different scores assigned to cancers based on the intensity of staining
in the biopsy specimen. The lower panel of Figure 1.1 displays representative IHC
staining for the individual scoring systems. A score of 0 or 1+ is considered
negative for HER2 expression, while a score of 2+ is an inconclusive result and
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cannot be deemed positive until fluorescence in situ hybridization assay is
performed to confirm amplification of HER2 (Rao et al., 2013).
Patients presenting with HER2+ breast cancer typically have high-grade
tumors characterized by poor cellular differentiation and high proliferative capacity.
These patients tend to have higher rates of recurrence and a higher rate of
metastasis than patients with HER2- breast cancer. A subset of HER2+ breast
cancer patients also have tumors positive for expression of ER, PR, or ER and PR
that are insensitive to hormone therapy, therefore, HER2-targeted therapy is
chosen over hormonal therapy to have a therapeutic benefit (Burstein, 2005; Perou
et al., 2000).
The monoclonal antibody (mAb), trastuzumab, is a targeted therapeutic with
specific inhibition against the ligand binding region of HER2, leading to a decrease
in HER2 levels and a reduction of HER2-mediated signal propagation.
Interestingly, despite the presence of HER2 molecules on the surface of normal
cells, trastuzumab is not efficacious in cells that are not deemed HER2+ (score of
3+).

This led to the realization that a higher threshold of HER2 expression,

compared to normal level cell expression, is required for targeted therapeutics to
be efficacious in this setting (Gutierrez and Schiff, 2011).
Even with the discovery of specific targeted therapies against ER, PR and
HER2, it became evident that not all patients treated with the appropriate targeted
drug elicited the same response to treatment. This variability in patient response
to treatment may be due in part to the relatively low percentage of cells that must
5

have positive staining of the corresponding receptor to be deemed positive. In the
setting of ER and PR staining, due to variable IHC standards amongst pathologists
for a tumor to be classified as “positive”, a range of 1-10% of cells are required to
have positive IHC staining; HER2 positivity must be identified in at least 10% of
the cells. The variability of the degree of positivity may explain the variability in
patient response to targeted therapeutics (Wolff et al., 2013), and HER2 positivity
must be identified in at least 10% of the cells. This variability in the degree of
positivity may explain the variability in patient response to targeted therapeutics.
Triple negative breast cancer
TNBC accounts for 10-20% of all breast cancers (Dent et al., 2007).
Patients presenting with TNBC often present with the disease at a younger age
than patients with other forms of breast cancer. When compared to other types of
breast cancer, TNBC patients tend to have highly proliferative cancers
accompanied by a poorer prognosis due to decreased progression-free survival
and overall patient survival (Schneider et al., 2008). Due to a lack of expression
of ER, PR, and HER2, TNBC patients do not benefit from hormonal and HER2
targeted therapies.

Currently, no available targeted therapeutics for TNBC

patients exist and patients are left with cytotoxic chemotherapies as their only
option for treatment (Boyle, 2012; Masuda et al., 2013; Podo et al., 2010a). TNBC
patients are given neoadjuvant chemotherapy as a pre-surgical treatment option;
patients that exhibit a pathological complete response (pCR), defined as the
absence of residual disease in the breast tissue after chemotherapy, are less likely
6

to recur than patients that do not obtain a pCR (Prat et al., 2014). TNBC is a
paradoxical disease in that while it is overly aggressive compared to other forms
of breast cancer, a substantial portion of TNBC patients have a favorable response
to chemotherapy (Carey et al., 2007). However, the subset of patients that do not
obtain a pCR are 75% more likely to recur and TNBC patients that recur have a
significantly shorter time to recurrence and die from metastatic disease (Carey et
al., 2007).
Five molecular subtypes of breast cancer
To better understand the variable response of patients to targeted therapy
and chemotherapy, researchers began to investigate the molecular mechanisms
governing the diverse types of breast cancers that present in the clinic. The
rationale behind these studies was that IHC staining would correlate with an
intrinsic gene expression profile, potentially offering new treatment strategies
aimed at increasing the efficacy of targeted inhibitors. In 2000, a group led by
Charles Perou worked towards elucidating the genetic profiles of breast cancer
with the hypothesis that the phenotypic diversity seen in the clinic would correlate
with diversity in the gene expression profiles of different cancers. Using cDNA
microarray of 42 individuals, they concluded that at least five different intrinsic
subtypes of breast cancer existed, matching the diversity observed in the clinical
setting (Perou et al., 2000).
Based on the conclusions of this study, breast cancers were classified into
Luminal A, Luminal B, HER2-positive, Basal-like and normal-like subtypes based
7

upon the expression patterns that emerged from their analysis. Remarkably, it
was determined that the intrinsic differences present between the subtypes
correlated with prognostic inferences, such as overall survival (OS) and relapsefree survival (RFS), that could be drawn about patients classified into the specific
subtypes. The ability of intrinsic gene expression patterns to also function as
prognostic indicators was striking, since patient outcome was not a determining
factor for defining the five breast cancer subtypes (Perou et al., 2000; Sorlie et al.,
2001).
The basal and luminal epithelia are the two types of epithelia cells that exist
in the human mammary gland. Basal cells can be identified by expression of the
basal keratins 5 and 6, while the luminal keratins 8 and 18 can be used to identify
luminal cells.

Two different luminal groups, Luminal A and Luminal B, were

identified from molecular stratification studies.

Patients diagnosed with the

Luminal A breast cancer subtype have tumors with ER+/PR+ staining without
positive expression, or amplification, of HER2 (Perou et al., 2000; Sorlie et al.,
2001). Sorlie et al., showed that patients in the Luminal A subtype group have the
best OD and RFS rate than the other four subtypes of breast cancer (Figure 1.2).
Tumors classified as Luminal A tend to have a low Ki67 index and indicating low
proliferative capacity, validating the high OS rates in these patients compared to
their Luminal B counterparts. In contrast, the Luminal B subtype tumors have
ER+/PR+/HER2+ staining coupled with a high Ki67 index. Luminal B patients have
significantly lower overall and relapse-free survival rates when compared to
8

patients with the Luminal A subtype. Gene expression profiling of Luminal A and
Luminal B subtypes revealed that these cancers arise from luminal cells within the
breast, however, differences in the intrinsic gene expression patterns between
these subtypes are responsible for governing their functional differences and
highlights the importance of understanding the molecular portraits of each subtype
(Sorlie et al., 2003).

Figure 1.2 Overall survival (OS) and relapse free survival (RFS) in the five subtypes of breast
cancer. The HER2+ and Basal breast cancer subtype groups have the lowest OS and RFS
amongst the five subtypes of breast cancer. Figure adapted from Sorlie et al. (Sorlie et al.,
2001)

Figure 1.2 shows that patients diagnosed with the normal-like subtype of breast
cancer had OS and RFS rates similar to those of the Luminal B subtype. Gene
expression analysis of tumors classified into the normal-like subtype revealed high
expression of genes associated with non-epithelial cell types, especially genes
associated with adipose tissue, and had high expression of basal epithelial cell
markers and low expression of luminal cell markers.
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Perou et al. also identified the HER2+ subtype of breast cancer
characterized by HER2+/ER-/PR- tumors. Subtyping of tumors within this group
revealed overexpression of genes associated with HER2 without expression of the
repertoire of genes correlated with luminal epithelial cells (Perou et al., 2000).
Approximately 15-30% of breast cancer patients are classified as having HER2+
cancer and patients presenting with this subtype have aggressive disease
associated with decreased overall survival and a decreased time to relapse. While
it was known that the HER2 oncoprotein was associated with a poorer prognosis
(Baselga et al., 1997), this study revealed, for the first time, that the basal-like
subtype was an indicator of poor prognosis and demonstrated that the basal-like
subtype potentially represented a new clinical entity associated with shorter overall
survival rates and p53 mutations (Sorlie et al., 2001).
Basal Breast Cancer
Approximately 15-20% of all breast cancers are classified as basal-like
breast cancers based on intrinsic gene expression profiling (Bertucci et al., 2012;
Nielsen et al., 2004; Sorlie et al., 2003). Patients presenting with basal-like breast
cancer present with high-grade disease accompanied by poor prognosis. These
cancers disproportionately affect African American women at higher rates than
women of other ethnicities (Nielsen et al., 2004). Basal-like breast cancers, due
to their lack of a specific molecular target, were originally not readily identifiable in
the clinical setting. Gene expression profiles of basal breast cancers revealed
tumors with increased expression of genes regulating signal transduction, cell
10

cycle and proliferation, cell survival, motility and invasion, and angiogenesis. A
subset of basal breast cancers is characterized by overexpression of the epidermal
growth factor receptor (EGFR), loss of PTEN expression coupled with activation
of the PI3’K/AKT signaling pathway, and TP53 mutations (Perou et al., 2000; Sorlie
et al., 2001; Sorlie et al., 2003).
Molecular Profiling of TNBC
Molecular stratification of breast cancer tumors not only revealed the
heterogeneity of breast cancer but highlighted the importance of understanding the
molecular differences present in these tumors. By gaining an appreciation for the
differences in gene expression that correlate to differences in patient outcome,
more emphasis can be placed on individualized patient care with the goal of
increasing overall survival. Shortly after the identification of the basal-like subtype,
it was appreciated that tumors within this group correlated with tumors in TNBC
(Dent et al., 2007; Rakha et al., 2007; Schneider et al., 2008). Due to the lack of
molecular targets in the basal-like and TNBC groups and the variable responses
of these patients to chemotherapy, studies aimed at characterizing and
understanding the gene expression profiles that may be present within these types
of breast cancer were initiated, with the goal of discovering targeted treatment
options for TNBC and basal breast cancer patients (Perou, 2010).
In 2011, Lehmann et al. sought to understand the molecular basis of TNBC
using genomic, molecular, and biological analyses in order to identify targeted
treatment strategies for these patients using genomic, molecular, and biological
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analyses to gain a robust portrait of this disease (Lehmann et al., 2011). Their
data revealed at least six distinct molecular subtypes of TNBC that also held
prognostic

significance:

Immunomodulatory

(IM),

mesenchymal

(M),

mesenchymal stem-like (MSL), luminal androgen receptor (LAR), basal-like 1
(BL1) and basal-like 2 (BL2) subtypes.

Initial reports attempted to assign

prognostic significance to the individual subtypes and initially highlighted the BL2
subtype as being particularly resistant to chemotherapy. However, as more studies
were conducted to determine the significance of molecular subtyping, it became
clear that the heterogeneity within these subtypes was still poorly understood and
that further studies investigating the molecular diversity within these groups
needed to be done (Abramson et al., 2015; Lehmann et al., 2011).
Criticism of the six TNBC subtypes
In 2013, research from Charles Perou’s group determined that the
classification of TNBC into six different subtypes was partially redundant due to
the large overlap of the subtypes with the claudin-low and PAM50 subtypes (Prat
et al., 2013). They also found that gene clustering of the M and MSL groups were
most likely influenced by the microenvironment and not indicative of the true nature
of tumor cells. Perou’s group also noted that the gene expression patterns of the
M, basal-like and LAR subtypes correlated with the gene expression profiles of
previously identified subtypes of TNBC. These observations led to the conclusions
that TNBC, especially in determining patient placement into clinical trials, should
be characterized as either basal-like or non-basal-like. While many experiments
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have been aimed at understanding the molecular mechanisms governing TNBC
(Burness et al., 2010; Cheang et al., 2008; Corkery et al., 2009; Lehmann and
Pietenpol, 2015; Pearl, 2012; Perou, 2010; Prat et al., 2014; Shah et al., 2012; Tan
et al., 2008), a consensus on specific biomarkers for this subtype remains elusive.
Common features of TN/basal breast cancer
The identification of molecular markers in TN and basal-like breast cancers
has been a common theme in breast cancer biology due to the aggressive
phenotypes of these cancers and the lack of established biomarkers for this
disease (Badve et al., 2011; Prat et al., 2013). Alterations in EGFR, PTEN and
p53 are common molecular events that have been identified as indicators of poor
prognosis in TN and basal-like breast cancer (Burness et al., 2010; Cheang et al.,
2008; Marty et al., 2008; Pires et al., 2013).
EGFR overexpression became solidified as a poor prognostic biomarker
when a study conducted by Harris et al. demonstrated that presence of ER-,
EGFR+ patients had significantly shorter time to relapse and decrease overall
survival rates than ER-, EGFR- patients (Harris et al., 1989). Further studies from
this group showed that the presence of EGFR in the primary tumor was a predictor
of poor response to endocrine therapy after relapse in both ER+ and ER- patients
(during this time ER- patients were also given endocrine therapy after relapse).
These data led the authors to conclude that clinical trials investigating the efficacy
of adjuvant chemotherapy should exclude patients with EGFR+ primary tumors;
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they suggested that adjuvant chemotherapy would likely be a better option for
these patients (Fox and Harris, 1997; Harris, 1991).
Tissue microarray analysis of immunohistochemical markers associated
with the basal subtype revealed that expression of EGFR was associated with the
basal-like intrinsic subtype (Sorlie et al., 2001). This led to the conclusion that
EGFR can be used as a marker for basal breast cancer. Gene expression profiling
was not a routine clinical procedure at the time; therefore, assays to specifically
identify the basal breast cancer subtype were needed to correctly identify the
basal-like patient population. Nielsen et al. revealed that EGFR, ER, HER2, and
cytokeratin 5/6 immunohistochemical staining could be used to identify basal
breast cancer patients (Nielsen et al., 2004). This panel of four antibodies proved
able to specifically identify basal-like breast cancers and was the first time that
EGFR expression had been specifically associated with the basal breast cancer
phenotype. Numerous studies have since revealed that EGFR alterations occur
in up to 70% of basal breast tumors (Cheang et al., 2008). EGFR has now been
established as an indicator of poor prognosis and led to the interest in EGFR as a
druggable molecular marker in basal breast cancer with overexpression of EGFR
(Harris et al., 1989).
PTEN is a tumor suppressor gene that functions by reversing the enzymatic
activity of PI3’Kinase enzymes (Maehama and Dixon, 1998). Loss, or decrease,
of PTEN expression occurs in about 50% of all breast cancers and has been
identified as an indicator of poor prognosis in breast cancer (Saal et al., 2008).
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During the time of PTEN’s discovery, the genetic events and pathways that were
involved in tumorigenesis were still largely unknown. Loss of heterozygosity (LOH)
screenings were done with the goal of understanding the gross genetic events that
could be contributing to tumor initiation and progression. LOH at the 10q23 locus
was identified in 9-21% of cases of sporadic breast cancer (Bose et al., 1998).
After PTEN was identified in this region, its association with Cowden’s Syndrome
and the increased probability of CS patients for developing breast cancer was
revealed and PTEN’s contribution to breast tumorigenesis began to unfold (Liaw
et al., 1997). . Bose et al. revealed that LOH at the 10q23 locus was associated
with loss of ER expression. This group also reported that patients with invasive
carcinomas harboring LOH at the 10q23 region tended to have high grade
aneuploid tumors (Bose et al., 1998).
PTEN loss was correlated with the basal-like breast cancers in an analysis
completed by the Cancer Genome Atlas Network (2012). They concluded that
loss of PTEN expression correlated with activation of PI3’Kinase activity and
hypothesized that these tumors may be sensitive to pharmacological inhibition of
the PTEN/PI3’Kinase/AKT pathway.
p53 is a nuclear tumor suppressor protein that contributes to genomic
stability through its role in cell cycle regulation (Sherr, 2004). TP53 mutations are
the most commonly occurring molecular alterations across the breast cancer
subtypes. Mutations in TP53 are strongly associated with the HER2+ and basallike breast cancer subtypes (Apostolou and Fostira, 2013; Domagala et al., 1993).
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In fact, up to 80% of basal-like breast cancers harbor TP53 mutations, often
resulting in an inactive protein. Mutant p53 is an indicator of poor prognosis in
basal-like breast cancer and has been correlated with positive node status and
poor overall survival (Sherr, 2004).
Cooperation of EGFR, PTEN and p53 in basal-like breast cancer
Numerous studies have identified EGFR overexpression, PTEN-loss and
mutant TP53 as common molecular alterations that occur in basal breast cancer.
Pires et al. investigated how combinations of these alterations affected mammary
epithelial cells.

Single manipulations of these proteins had been previously

characterized in MCF10A cells; single alterations resulted in an altered phenotype
in the MCF10A cell line but did not lead to transformation of the cells (Pires et al.,
2013). Pires et al demonstrated that EGFR overexpression in combination with
PTEN loss and inactive p53 cooperated to transform the MCF10A cell line; these
cells were able to form colonies in soft agar and demonstrated the ability to
proliferate independent of growth factor stimulation in vitro, . Thus, it is possible
that these genetic alterations form a cooperative network that results in basal-like
breast cancer initiation and progression.
To better understand the significance of this potential signaling network in
basal-like breast cancer, She et al. analyzed 116 breast tumors to assess the
correlation between the incidence of EGFR, PTEN and p53 alterations and to
determine

if

a

combinatorial

treatment

strategy,

targeting

EGFR

and

PTEN/PI3’Kinase activity, would be efficacious within this subset of patients (She
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et al., 2016). Their data revealed that PTEN/PI3’Kinase activity was elevated in
ER- and basal-like breast tumors and demonstrated a positive correlation between
PTEN loss and EGFR overexpression. They also determined that PTEN loss and
EGFR overexpression positively correlated with the basal-like breast cancer
subtype. Based on these results, they concluded that dual targeting of EGFR and
PTEN/PI3’Kinase

would bypass

the resistance

mechanisms

seen with

monotherapy. The authors targeted both EGFR and PI3’Kinase activity using
small molecule inhibitors and determined that these inhibitors synergized to inhibit
basal-like breast cancer cell line growth in vitro and a reduction in tumor volume in
vivo (She et al., 2016).
Based on the results of these studies, the subset of basal-like breast cancer
patients characterized by EGFR overexpression, PTEN-loss and mutant TP53
represent a clinical entity with a poor prognosis and intrinsic resistance to
chemotherapeutics. Understanding the molecular mechanisms governing this
tumor subtype will lead to the design of rational treatment strategies for patients
with these characteristics.
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Epidermal Growth Factor Receptor protein
The epidermal growth factor
receptor (EGFR) is a 170 kDa
transmembrane receptor tyrosine
kinase that belongs to the Erb-B
family of receptors.

EGFR (Erb-

B1), HER2 (Erb-B2), HER3 (ErbB3) and HER4 (Erb-B4) are the
four members of this class 1
transmembrane protein family that
can homo- and heterodimerize with
each other to facilitate downstream
signal propagation.

Members of

the Erb-B family of receptors exist
Figure 1.3 EGFR Structure. Schematic identifying the

as monomers and dimers in their domains of EGFR. The extracellular domain is
non-stimulated
ligand

binding

state;

however,

results

in

a

conformational change that leads

separated into four subdomains; domain I is
responsible for ligand binding. The intracellular
domain is composed of three subdomains: the
juxtamembrane domain, tyrosine kinase domain and
regulatory domain. Receptor tyrosine kinase
inhibitors bind within the ATP pocket located in the
tyrosine kinase domain (Flynn et al., 2009)

to activation of the receptors (Baselga et al., 1997; Fox and Harris, 1997; Harris et
al., 1989).
The crystal structure of EGFR revealed an extracellular domain (ECD) that
controls signal propagation, a transmembrane domain (TMB) that functions to
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tether the receptor to the lipid bi-layer, and an intracellular domain (ICD) (Figure
1.3). The intracellular domain contains three subdomains: the juxta-membrane
domain (JMD), the tyrosine kinase domain (TKD) and the regulatory domain (RD)
(Flynn et al., 2009).
EGFR is broadly distributed in adult tissues with higher expression of the
receptor found in the dermal, nervous, cardiovascular and gastrointestinal cells
(Cancer Genome Atlas, 2012). EGFR signaling contributes to numerous cellular
processes such as proliferation, invasion, angiogenesis, evasion of apoptosis,
survival, cell migration and metastasis (Scaltriti and Baselga, 2006).
Epidermal Growth Factor Receptor Dysregulation
In 2004, Nielsen et al. aimed to develop a defined mechanism to identify
basal breast cancer patients clinically. Using a panel of basal-like tumors, they
identified a four panel IHC profile to clinically identify the basal breast cancer
subtypes. Staining with ER, HER1 (EGFR), cytokeratin 5/6 and HER2 antibodies
was able to accurately identify the basal breast cancer subtype in a clinical setting
(Nielsen et al., 2004). This was the first time in that EGFR had been confirmed as
a prognostic tool in breast cancer and was the birth of the EGFR field in breast
cancer biology. Due to this relatively new association of EGFR expression and the
basal breast cancer subtype, not much was understood about the regulation of this
receptor in this subtype of cancer (Baselga and Arteaga, 2005; Ono and Kuwano,
2006; Scaltriti and Baselga, 2006). Based on analyses of public databases such
as cBioPortal and TCGA, it can be concluded that mutations in the EGFR are not
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common genetic alterations found in breast cancer patients.

Instead, EGFR

dysregulation typically presents as gene amplification and overexpression of
EGFR and its ligands, and high expression of EGFR in breast cancer patients
correlates with worse OS and worse disease-free survival (Ono and Kuwano,
2006; Park et al., 2014; Tomas et al., 2014).
Epidermal Growth Factor Receptor Activation
Ligand binding within the ECD domain results in receptor dimerization and
downstream signal propagation (Burgess et al., 2003). At least 7 ligands that can
interact with the ECD of EGFR and other members of the Erb-B family have been
identified: epidermal growth factor (EGF), transforming growth factor alpha (TGFa), amphiregulin (AREG), epiregulin (EPR), betacellulin (BTC), epigen (EPG), and
heparin binding epidermal growth factor (HB-EGF) (Willmarth and Ethier, 2008).
EGF, AREG and TGF-α bind specifically to EGFR, while the other ligands can bind
to and activate different combinations of dimerized family members (Harris, 1991;
Schneider and Wolf, 2009). To date there is no ligand for the HER2 receptor. All
ligands are expressed as integral membrane proteins that are proteolytically
processed to yield the mature ligand (Farooq, 2015).
Ligand binding to EGFR (Erb-B1), Erb-B3 and Erb-B4 promotes
dimerization of the receptors and increases their dimerization with Erb-B2; this
dimerization results in receptor activation (Schneider and Wolf, 2009). Activation
of the kinase domain within EGFR sets off a signaling cascade that is facilitated
through the binding of adaptor proteins to the phosphorylated residues, leading to
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downstream signaling propagation. The RD is the location of the activation loop
and the active site of the C-terminal tail (C-tail). The C-tail is the only domain of
the EGFR whose crystal structure has yet to be resolved due to its instability.
However, despite limited information, it is known that the C-tail becomes autophosphorylated and that these phospho-residues form docking sites for SH2 and
PTB domain-containing adaptor proteins, leading to activation of various signaling
cascades (Figure 1.3)(Flynn et al., 2009). The TKD and the RD of the intracellular
domain is where EGFR targeted tyrosine kinase inhibitors bind to prevent
downstream signal propagation. Once the EGFR has become active, the receptor
is typically endocytosed, removing the receptor from the cell surface and inititating
receptor recycling and degradation (Ono and Kuwano, 2006; Scaltriti and Baselga,
2006; Tomas et al., 2014).
Epidermal Growth Factor Receptor targeting
Efforts at targeting the EGFR have focused on the ECD, which is
responsible for ligand binding and subsequent signal transduction, and the ICD,
which contains the ATP site that controls tyrosine phosphorylation. Two major
classes of molecules that have been developed to target these domains are
monoclonal antibodies (mAb) and tyrosine kinase inhibitors (TKi) (Scaltriti and
Baselga, 2006). mAbs act as competitive inhibitors and compete with ligands in
the ECD. Binding of the mAb to the EGFR still results in receptor internalization
and subsequent degradation resulting in attenuation of EGFR signaling; however,
the rate of internalization happens at a rate 10-fold slower than that of ligand21

stimulated receptors (Tomas et al., 2014). Cetuximab was the first mAb against
EGFR used to treat metastatic colon cancer (Ono and Kuwano, 2006).
TKi’s are low molecular weight drugs that function through two different
mechanisms: competitive inhibition within the ATP binding pocket or allosteric
inhibition caused by a conformational change occurring after binding of the TKi
near the active site (Arora and Scholar, 2005). The first small molecule inhibitor
against EGFR to receive FDA approval was Gefitinib (Cohen et al., 2003). Gefitinib
is a potent inhibitor of the tyrosine kinase activity of EGFR and is enzymatically
selective against the other Erb-B family members (Herbst et al., 2004). To
determine efficacy of Gefitinib to inhibit EGFR signaling, skin biopsies were taken
from patents before and after treatment and were assessed for activated EGFR. A
common side effect of effective EGFR inhibition is the formation of a rash due to
the function that EGFR has in the basal layer of the epidermis (Holcmann and
Sibilia, 2015).
Phase II clinical trials revealed a relatively low toxicity of gefitinib in patients,
which highlights the benefit of targeted therapeutics (Baselga et al., 2005).
Although chemotherapeutic cytotoxic drugs are effective at targeting the rapidly
proliferating cells located within tumors, they are not selective over normal cells
with a high proliferative capacity, such as bone marrow cells, hair follicles and cells
of the digestive tract (Smith et al., 2007). Therefore, patients undergoing
chemotherapy present with side effects as immunosuppression, mucositis, and
alopecia. Chemotherapeutics are often given at the maximum tolerated dose
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(MTD) (the concentration of drug that can be administered to patients without
causing unacceptable side effects) despite the minimal effective dose (MED) (the
concentration at which no further efficacy would be seen with a higher dose) falling
well below the MTD. In appropriate patient populations, using biologically targeted
drugs, like Gefitinib, is a better treatment strategy for patients with cancer. Gefitinib
functions effectively at a dose well below the MTD concentration, which allows for
administration of the drug at the optimal biological dose, allowing for maximum
efficacy with high patient safety (Baselga et al., 2005).
The success of EGFR inhibition depends on how closely EGFR-driven
signaling pathways are coupled to receptor activation. Research in our laboratory
has focused on the uncoupling of the EGFR signaling pathway in the SUM-149
cell line. The SUM-149 cell line is a PTEN-null, p53 mutant, phospho-AKT high,
EGFR overexpressing cell line that was created from the primary tumor of a patient
presenting with inflammatory TNBC (Kappler et al., 2015). Our laboratory
demonstrated that despite overexpression of this receptor and elevated AKT
activity in these cells, inhibition of the EGFR was ineffective at reducing AKT
phosphorylation. Gefitinib’s inability to reduce AKT phosphorylation in these cells
suggests that a patient whose disease state matched that of this cell line would not
benefit from single agent treatment with gefitinib. Treatment strategies utilizing
targeted inhibition of EGFR in combination with other inhibitors that are effective
at reducing AKT phosphorylation may prove to be beneficial in a clinical setting
(Corkery et al., 2009). Interestingly, the resistance of this TNBC cell line to gefitinib
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recapitulated the data presented in clinical trials in which gefitinib failed to show a
clinical benefit (Comis, 2005; Smith et al., 2007; von Minckwitz et al., 2005).
PTEN
Phosphatase and tensin homolog deleted on chromosome 10 is a tumor
suppressor protein that primarily functions as a negative regulator of the
PI3’Kinase pathway (Maehama and Dixon, 1999). Isolated by three independent
groups in 1997, PTEN shares high sequence homology to tensin, auxilin and other
dual specificity phosphatases (Liaw et al., 1997). Although PTEN is widely viewed
as a dual specificity phosphatase acting on both lipids and proteins, studies
examining the protein phosphatase activity of PTEN have been limited and
inconsistent. In contrast, the lipid phosphatase activity of PTEN has been
extensively studied (Iijima et al., 2004; Maehama and Dixon, 1998; Maehama and
Dixon, 1999; Sansal and Sellers, 2004; Yin and Shen, 2008).

Figure 1.4 PTEN Structure: PTEN is 403 amino acids in length, producing a protein product with a
molecular weight around 47 kDa. The phosphatase and the C2 domain were the only structures
capable of being resolved in the crystal structure of PTEN. The crystal structure of PTEN was only
able to resolve amino acids 14-351; the flexible C-tail was not identified in the crystal structure and
it was not until later that the C-tail and its motifs were discovered. PDB- phosphatidylinositol-4,5bisphosphate-binding domain. PDZ-(PSD95, Dlg1, Zo-1 homology) domain.
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PTEN protein
PTEN is a 47 kDa protein located at the 10q23 locus, a region of the
genome frequently associated with loss of heteroygosity (LOH) and tumor
progression (Bose et al., 1998; Saal et al., 2008). The crystal structure of PTEN
revealed two major domains: the N-terminal phosphatase domain and a C-terminal
C2 domain (Figure 1.4) (Das et al., 2003). The phosphatase domain and the C2
domain together function as the catalytic subunit of PTEN (Trotman, 2010). These
two domains function as a catalytic subunit; the N-terminal catalytic phosphatase
domain contains an active site that accomodates the large phosphoinositide head
group and cooperates with the C2 domain to exert its phosphatase function (Das
et al., 2003). The C2 domain is required for binding of PTEN to phospholipid
membranes and contibutes to the stability of the phosphatase domain.
Interestingly, the C2 domain lacks the canonical Ca2+ chelating residues found in
other C2 domains, suggesting that PTEN is capable of binding to the plasma
membrane in a calcium-independent manner.

However, the significance of

PTEN’s non-canonical C2 domain has not been extensively studied. The C2
domain also contains numerous serine and theronine residues that, upon
phosphorylation, regulate PTEN function and stability (Das et al., 2003; Trotman,
2009; Trotman, 2010).
Further studies of PTEN’s structure revealed that the N-terminus begins
with a phosphatidylinositol-4,5-bisphosphate-binding (PtdIns (4,5)P2) domain
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(PBD) that contributes to the translocation of PTEN to the membrane surface and
contributes to it catalytic activity (Iijima et al., 2004).
The C-terminal tail (C-tail) of PTEN is a long flexible portion of the protein
that is post-transcriptionally modified and contributes to the regulation of PTEN
function and stability (Wang and Jiang, 2008). Phosphorylation of residues within
the C-tail results in PTEN’s cytosolic localization, whereas dephosphorylated
PTEN translocates to the plasma membrane and functions as a lipid phosphatase.
It is now understood that the phosphorylated C-tail interacts with the C2 domain,
resulitng in a closed conformation of the PTEN protein. This causes dissociation
of the C2 domain from the plasma membrane and prevents PTEN from interacting
with PIP3. This C-tail/C2 domain interaction prevents ubiquitination of PTEN at
lysine residues, leading to increased protein stability (Das et al., 2003; Wang and
Jiang, 2008).
The PDZ (PSD95, Dlg1, zo-1 homology) domain is a motif located within
the C-tail that is suggested to contribute to the stabilization and regulation of PTEN.
However, in contrast to this hypothesis, a study conducted by Das et al. concluded
that the stability of PTEN was not dependent upon the C-tail fragment but rather
was dependent upon the phosphatase activity of PTEN (Das et al., 2003).
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PTEN Function
The homology of PTEN’s phosphatase domain to other dual specificity
phosphatases led to the hypothesis that PTEN functions as a protein phosphatase;
however, studies revealed that PTEN had weak activity as a protein phosphatase
in vitro and in vivo (Maehama and Dixon, 1998). It was later determined that PTEN
had high specificity for acidic substrates and it was hypothesized that PTEN’s
phosphatase activity would have higher specificity for non-proteinaceous
substrates like phosphoinositides (Maehama and Dixon, 1998; Maehama and
Dixon, 1999).
The lipid phosphatase activity of PTEN results in the direct negative
regulation of
extracted

PI3’Kinase enzymes. Maehama et al. demonstrated that lipid

from

PTEN-expressing

293

cells

had

decreased

levels

of

phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) compared to control;
interestingly, the decrease in PtdIns(3,4,5)P3 occurred without decreasing
PI3’Kinase activity. It was revealed that PTEN dephosphorylated the D3 positiion
of the inositol ring of PtdIns(3,4,5)P3 to produce PtdIns(4,5)P2 (Maehama and
Dixon, 1998). This was the first time that PTEN was identified as a 3’ phosphatase,
and later studies revealed that PTEN had substrate specificity for PtdIns(3)P and
PtdIns(3,4)P2, with a greater preference for PtdIns(3,4,5)P3. By directly opposing
the activity of PI3’Kinase, PTEN acts as a molecular switch that suppresses
PI3’Kinase dependent signal propagation, and loss of PTEN activity results in the
accumulation of PtdIns(3,4,5)P3 and abberant PI3’Kinase signaling. Loss of PTEN
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expression mimics PI3K3CA mutations, and these two events have been found to
be mututally exclusive, as both loss of PTEN and activating Class I PI3’Kinase
mutations (PIK3CA mutations) would have redundant function since both lead an
increase in PtdIns(3,4,5)P3 (Saal et al., 2007).
The cellular localization of PTEN determines the role that PTEN has in a
specific compartment. Cytoplamic PTEN exists in a non-activated conformation in
which the C-terminal tail of PTEN covers the catalytic site of the protein (Wang and
Jiang, 2008). Recruitment of PTEN to the plasma membrane via its PH domain
leads

to

an

open

conformation,

allowing

PTEN

to

dephosphorylate

PtdIns(3,4,5)P3, thus opposing the activity of PI3’Kinases (Das et al., 2003). This
subsequently influences downstream signaling cascades associated with cellular
processes such as proliferation, cell polarity, migration and apoptosis (BlancoAparicio et al., 2007).
Nuclear PTEN contributes to the maintenance of genomic stability by
regulating the cell cycle, contributing to double strand break (DSB) repair, and
maintaining chromosomal stability (Bassi et al., 2013). Because PTEN has no
classic nuclear localization signal, the exact mechanims by which PTEN is able to
shuttle in and out of the nucleus remain unclear. Evidence for the important role of
PTEN in the genomic stabilty of cells is strengthened by the co-localization of
PTEN to centromeres, which are critical for proper cellular division to occur during
the transition from metaphase to anaphase (Milella et al., 2015).
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PTEN in disease pathology
Soon after PTEN was identified, germline mutations of PTEN were found to
be associated with Cowdens Syndrome (CS) (Liaw et al., 1997). It was determined
that approximately 85% of patients presenting with the autosomal dominant
disorder harbored germline mutations of PTEN; these patients were also
predisposed to the development of breast, thyroid and kidney cancer. C124S and
G129E are the most common PTEN mutations associated with CS and occur in
the phosphatase domain of PTEN, suggesting that the phosphatase domain of
PTEN contributes to its role as tumor suppressor. Iijima et al., investigated the
effect of mutations within PTEN and their influence on its subcellular location, and
revealed that while mutations within the phosphatase domain had no bearing on
localization, they disrupted the ability of PTEN to regulate levels of PtdIns(3,4,5)P3.
The C124S and G129E mutations led to higher levels of PtdIns(3,4,5)P3 when
compared to levels of PtdIns(3,4,5)P3 in the presence of WT PTEN (Iijima et al.,
2004).
PTEN hamartoma tumor syndrome (PHTS) is a group of disorders,
including CS, characterized by germline PTEN mutations (Pilarski et al., 2013).
Like CS, theses disorders result in the formation of multiple benign hamartomas,
tumor-like masses resembling the tissue from which they arise. Patients presenting
with PHTS have a increased risk for the formation of numerous cancer types
including breast cancer, endometrial cancer and melanoma. In fact, individuals
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diagnosed with PTHS are seven times more likely to develop breast cancer than
the average woman (Pilarski et al., 2013).
Numerous germline mutations of PTEN have been indentified, with
approximately 40% of them located in the phosphatase domain; however, cancercausing mutations are present in all domains of the PTEN gene (Yin and Shen,
2008). This suggests that the tumor suppressive capability of PTEN is multifaceted
and not only driven by the lipid phosphatase activity of PTEN .
PTEN loss is observed in about 20% of solid tumors samples . Loss of
PTEN protein is an indicator of poor prognosis in glioblastoma multiforme, prostate
cancer and breast cancer, and mutations in PTEN have been directly linked to
melanoma, NSCLC and thyroid cancer (Keniry and Parsons, 2008; Liaw et al.,
1997; Stahl et al., 2004).
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Receptor tyrosine kinase/PI3’Kinase/AKT signaling pathway
PTEN genomic alterations have been associated with activation of the
PI3’Kinase signaling pathway within the basal-like breast cancer subtype (Marty et
al., 2008; Saal et al., 2008). Phosphorylated AKT (phospho-AKT) is used as a
marker of PI3’Kinase activity, and studies focusing on basal-like breast cancer
have demonstrated a significant increase in phospho-AKT when compared to nonbasal tumors (Fresno Vara et al., 2004). Activation of receptor tyrosine kinases,
such as HER2, IGFR and EGFR, lead to downstream signal propagation through
PI3’kinase signaling cascade.

Figure 1.5 is a representative schematic of

Figure 1.5 Canonical PI3'Kinase signaling pathway. Activated PI3’Kinase results in the
formation of PIP3, which in turn leads to AKT membrane localization and activation
pathway activation.(Manning and Cantley, 2007)
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canonical PI3’Kinase signaling initiated by receptor tyrosine kinases (RTKs)
(Manning and Cantley, 2007; Yuan and Cantley, 2008).
The binding of a ligand to the extracellular domain of RTKs causes a
conformational change within the receptor promoting dimerization.

Receptor

dimerization results in auto- and trans-phosphorylation of the RTK within the
tyrosine kinase domain (TKD) (Fresno Vara et al., 2004). Activation of the TKD
generates phosphorylated tyrosine residues, which then serve as docking sites for
adaptor proteins such as Grb2 (Tomas et al., 2014). Binding of Grb2 to the TKD
of activated RTKs facilitates recruitment the PI3’Kinase p85 regulatory molecule,
which is linked to a Class I PI3’Kinase p110 catalytic enzyme (Yu et al., 1998).
The p85 regulatory molecule binds to the p110 catalytic subunit through SH2
domain interactions in both proteins, and the Grb2-p85-p110 association enables
the p110 enzyme to be near the plasma membrane and its phosphoinositide
substrates. The catalytic subunit functions by phosphorylating the 3’ position
hydroxyl group of inositol rings of phosphatidylinositols (PtdIns), resulting in the
formation of PtdIns(3,4,5)P3 (PIP3) from PtdIns(4,5)P2 (Franke et al., 1997a).
PIP3 acts as a lipid second messenger leading to the cellular re-localization
of AKT and 3-phosphoinositide-dependent protein kinase 1 (PDK1) to the inner
leaflet of the plasma membrane through the binding of their PH domains to PIP3.
Localization of AKT and PDK1 to the cell surface places these proteins near each
other, allowing PDK1 to phosphorylate AKT at the Thr308 site (Fresno Vara et al.,
2004). Phosphorylation of AKT at the Thr308 site is required for activation of the
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AKT kinase; however, full activation of AKT is achieved when AKT is
phosphorylated at the Ser473 site by PDK2, commonly considered to be the
mTORC2 complex (Osaki et al., 2004).

Activated AKT phosphorylates

downstream substrates such as mTORC1, BAD, EIF4B, IKK-a, and S6, therefore
contributing to the regulation of cellular processes such as cell survival, apoptosis,
transcription, immune response, and protein synthesis (Manning and Cantley,
2007).
PTEN’s function as a 3’phosphatase results in the dephosphorylation of the
3’ phosphate group of PIP3 lipid second messengers to produce PtdIns (4,5) P2.
Reduction of PIP3 levels corresponds with a reduction of AKT activation.
Despite the simplified nature of diagrams depicting RTK activation of
PI3’Kinase and AKT, the RTK/PI3’K/PTEN/AKT signaling pathway is complex,
regulates numerous cellular processes and contains many potential nodes of
dysregulation that can ultimately lead to tumorigenesis.
Discovery of PI3’Kinase
The study of PI3’Kinase signaling began in 1987 when Kaplan et al.
identified an 85 kDa phosphoprotein that coincided with PDGF stimulation of NIH
3T3 cells transformed by SV40 middle T antigen (Kaplan et al., 1987). At this point
in time, it was understood that PDGF and MTAg transformation exerted their
stimulatory effects by increasing phosphatidylinositol (PI) turnover, resulting in the
formation of PIP and PIP2 species that had been implicated in being regulated by
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growth factor receptor stimulation and oncogenic transformation (HasegawaSasaki, 1985).

Kaplan et al. showed that MTAg transformation and PDGF

stimulation resulted in the phosphorylation of this 85 kDa protein, and that this
protein either functioned as the kinase responsible for PI turnover or was a
substrate of the kinase involved in the formation of PI derivatives (Kaplan et al.,
1987). However, the mechanisms by which PI3’Kinase products were translating
signals into cellular processes were still largely unknown.
The first insight into the function of PI3’K products was the discovery of 100
amino acid repeats within the pleckstrin protein, a major substrate of protein kinase
C (PKC) in platelets (Haslam et al., 1993; Musacchio et al., 1993). It was later
discovered that this 100 amino acid sequence was present not only in pleckstrin,
but was also abundant in other signal transduction proteins such as AKT, GAPs
and phospholipase C, and was named the pleckstrin homology (PH) domain
(Musacchio et al., 1993). Due to the relatively small size of the sequence, it was
concluded that enzymatic activity within this domain was unlikely. It was
hypothesized that the sequence may be involved in molecular recognition, yet the
functional significance of the recognition was unknown. In 1994, Feisk and Harlan
showed that the PH domain of proteins binds with high affinity to phosphoinositides
(Harlan et al., 1994). A study by Touhara et al gave additional insight into the
significance of the PH domain with the finding that the β-adrenergic receptor (BAR)
was phosphorylated by kinases (BARK) following translocation to the cellular
membrane (Touhara et al., 1995). Further studies identified the PH domain as the
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region of BARK that was involved in membrane localization (Dhand et al., 1994).
Later, in 1995, it was shown that the PH domain of BARK interacted with PI(4,5)P2
(Harlan et al., 1995). Subsequent studies aimed at characterization of the
Structural interaction of the PH domain led to the discovery of how PI3’K signaling
molecules were translating downstream signaling events when it was shown that
AKT, which was known to have a PH domain, was an effector of PI3’Kinase
signaling (Datta et al., 1996).
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Structure and Function
PI3’Kinases are members of a family of enzymes that catalyze the
phosphorylation of the 3’hydroxyl group (D3) present in the inositol rings of
phosphatidylinositols. There are four classes of PI3’K family members: Class I,
Class II, Class III and Class IV (Liu et al., 2009). The Class I’s are further
characterized into Class Ia and Class Ib enzymes comprised of both a regulatory
and catalytic enzyme capable of heterodimerizing via their SH2 domains, which
causes a conformational change to occur within the catalytic enzyme, thereby
activating it. (Zhao and Vogt, 2008) This activated enzyme is now able to facilitate
the phosphorylation of its substrates leading to downstream signal transduction.
Class II PI3Ks are comprised of three catalytic isoforms; however, this class does
not have a regulatory subunit (Fruman et al., 1998; Traer et al., 2006). Class III
PI3’Kinase is comprised of a single catalytic and regulatory isoform (Fruman et al.,
1998).

Figure 1.6 Formation of Phosphatidylinositide Lipid Second Messengers with emphasis
on specific PI3’Kinase Class participation.
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The catalytic and regulatory subunits differ in both structure and function.
While the catalytic proteins contain kinase domains lending to the enzymatic
activity of the PI3’Kinase family of enzymes, the regulatory enzymes contain SH2
domains allowing for these enzymes to bind to phosphorylated tyrosine sites on
activated receptors. Binding of the regulatory subunit allows the catalytic subunit
to become active to facilitate downstream signaling (Yu et al., 1998).

Phosphatidylinositols (PtdIns): PtdIns are members of the phosphatidylglycerol
family, composed of a diacylglyceride molecule joined to an inositol ring through a
phosphodiester linkage. These molecules form a minor component of the inner
leaflet of eukaryotic cell membranes.

The role of PI3’K enzymes is to

phosphorylate the D3 position of inositol rings to activate downstream signaling
pathways.

D3 phosphorylation has been implicated in numerous cellular

processes such as cellular membrane trafficking, docking PH domains, and
activating downstream signaling molecules (Divecha and Irvine, 1995; Thapa et
al., 2016).
Class I
The Class I PI3’K family of enzymes is the most commonly studied PI3’K
family in human disease and canonically are responsible for the production of
PtdIns(3,4,5)P3 (Zhao and Vogt, 2008). The Class I PI3’Kinase family is divided
into Class Ia and Class Ib enzymes based on their mode of activation. Class Ia
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PI3’Kinase enzymes are activated in response to RTKs stimulation whereas the
Class Ib enzymes are activated through G-protein coupled receptor (GPCR)
stimulation. Class Ia is comprised of three p110 enzymes encoded by the genes
PIK3CA, PIK3CB and PIK3CD corresponding to the α, β, and δ isoforms. Class
Ia also contains regulatory subunits encoded by PIK3R1 (p85α), PIK3R2 (p85β)
and PIK3R3 (p55γ) (Fruman et al., 1998).
The p85/p55 regulatory subunits bind to tyrosine phosphorylated residues
on activated receptors or adaptor proteins, allowing for the p110 enzyme to bind
to activated receptors (Yu et al., 1998; Zhao and Vogt, 2008). P110α and p110β
are the most ubiquitously expressed of the Class I PI3’K enzymes in tissues and
the p110δ enzyme is the most common isoform expressed in leukocytes. The
p110 isoforms have similar structure in that they are composed of an N-terminal
adaptor binding domain (ABD), followed by a C2 domain, a helical domain, and a
catalytic kinase domain.

The regulatory domain contains src homology (SH)

domains responsible for the interaction of the regulatory protein with the p110
catalytic proteins (Fresno Vara et al., 2004; Sansal and Sellers, 2004; Zhang and
Yu, 2010). Some of the p85 regulatory proteins contain an SH3, proline rich
domain and a BCR domain, which allows for the p85 subunit to interact with
GTPases.

According to cBioPortal, PIK3CA is the most commonly mutated

catalytic enzyme of the PI3’Kinase family and is altered in 34% of breast cancer
samples (Figure 4.1).
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Class II
PIK3C2A, PIK3C2B, and PIK3C2G are the three genes that encode for the
Class II α, β, and γ lipid kinases (Liu et al., 2009). These enzymes catalyze the
synthesis of the PtdIns(3)P and PtdIns(3,4)P2 second messengers. PIK3C2A and
PIK3C2B are the most widely expressed of the Class II molecules and have been
specifically implicated in regulating cellular processes such as activation of cell
surface receptors, migration, survival, and endocytosis (Mountford et al., 2015).
These molecules differ from the Class I catalytic subunits by the additional cterminal C2 domain and the Phox homology (PX) domain, which contributes to the
signaling specificity of these enzymes (Traer et al., 2006).
PIK3C2A is located on chromosome 11 (11p15.1) and protein expression
of PIK3C2A is ubiquitous in human tissue types. Studies aimed at understanding
the isoform specific function of PIK3C2A have revealed its contribution to many
cellular processes including apoptosis, autophagy, cell proliferation and growth,
dynamin-independent endocytosis, smooth muscle contraction and insulin
stimulation. Interestingly, this isoform is insensitive to nanomolar doses of the pan
class PI3’Kinase inhibitor, wortmannin (Domin et al., 1997).
PIK3C2B is located on chromosome 1 (1q32.1) and is ubiquitously
expressed throughout the human body (Cancer Genome Atlas, 2012).

This

isoform has been shown to be regulated by epidermal growth factor and stem cell
factor signaling and has been implicated in migration and tumorigenesis.
According to cBioPortal data, PIK3C2B is the most commonly amplified
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PI3’Kinase, resulting in a great deal of interest in this isoform as a causative agent
in tumorigenesis (Mountford et al., 2015; Traer et al., 2006).

Interestingly,

PI3’KinaseC2B has been specifically implicated in breast cancer along with other
proteins that have been identified as amplified in breast cancer; a study by Waugh
identified a 1q amplicon containing PIK3C2B, PI4KB, PIP5K1A, and AKT3
(Waugh, 2014). Cooperation of these enzymes, which are all related to
phosphatidylinositol signaling, is a likely signaling hub present in a subset of breast
cancers which could be a potential therapeutic target.

Studies aimed at

understanding the biology of this isoform have been limited to genetic studies
utilizing knockdown of protein levels and inhibition through non-specific inhibitors;
this has increased the interest in the identification and development of Class IIspecific inhibitors.
PIK3C2G is located on chromosome 12 (12p12.3) and is the least studied
of the Class II PI3’Kinase isoforms (Rozycka et al., 1998). The PIK3C2G isoform
is preferentially expressed in the stomach, skin, liver, kidney, small intestine and
gall bladder. The protein was linked to the development of type II diabetes in a
cohort of Japanese patients, suggesting that this enzyme contributes to insulin
resistance (Daimon et al., 2008). In mice, PIK3C2G is preferentially expressed in
the liver and pancreas, and the livers of PIK3C2G

-/-

mice displayed decreased

levels of glycogen compared to control animals, suggesting that these animals
were insulin resistant (Braccini et al., 2015). Concordantly, PIK3C2G -/- mice were
significantly less sensitive to insulin than control mice. These data taken together
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suggest an isoform specific role for PIK3C2G in the regulation of glycogen
synthase production and insulin resistance (Braccini et al., 2015).
Class III The class III PI3’Kinase family is composed of the catalytic isoform,
Vsp34, which catalyzes the formation of PI(3)P from PtdIns. Vsp34 is known as a
housekeeping enzyme due to the ubiquitous expression of PI(3)P and the fact that
it is not implicated in the activation of key signaling kinases. Despite its limited
kinase function, PI(3)P has been identified as an integral component of vesicular
transport, protein sorting, autophagy regulation and nutrient signaling. Vsp34 is
also known to interact with the p150 regulatory protein; however, little is known
about this interaction (Ronan et al., 2014).
Class IV
The class IV PI3’Kinase family is composed of multiple PI3’Kinase-related
enzymes with structures and functions similar to those of the Class I, II, and III
PI3’Kinase enzymes (Liu et al., 2009). Proteins included in this class are DNAPK, ATM, and mTOR, which are all serine or threonine protein kinases. These
proteins are all responsive to nanomolar concentrations of wortmannin (Kuete et
al., 2015).
Targeting the PI3’Kinase pathway
Residues within the phosphate-binding (P-loop) and activation loop of the
PI3’K family of enzymes vary amongst the classes and this variability leads to the
specificity of the lipid substrates (Pirola et al., 2001). The P-loop of the Class I
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enzymes are very heterogeneous, which allows for the specificity of inhibitors
targeting these enzymes (Liu et al., 2009).
Mechanisms behind PI3’Kinase pathway resistance
Adaptive resistance mechanisms are commonplace in patients that have
been treated with a PI3’Kinase targeted therapeutics and occur within hours to
minutes of drug administration. Frequently, in this type of resistance, non-genetic
changes occur in the cells to create bypass mechanisms of signaling to overcome
inhibition. Rebound signaling, in which other molecules increase in expression or
activity, allows for inhibition of one pathway to be circumvented by the upregulation
of another pathway. Examples of rebound signaling include the increased signaling
of PI3’Kinase downstream targets by upregulation of FOXO-driven signaling
pathways and the increased expression of RTKs, which result in constitutive
activation of the pathway (Rodon et al., 2013). In an effort to prevent the effects
of rebound signaling, clinical trials assessing the efficacy of dually targeting RTKs
and PI3’Kinase isoforms have been designed.

Another common adaptive

response that occurs in the presence of PI3’Kinase targeted therapeutics is
isoform compensation. This occurs when the function of a specific isoform that
has been selectively targeted by a PI3’Kinase inhibitor can be compensated for by
the function of another isoform due to the redundant functionality of many of the
PI3’Kinase isoforms (Lee et al., 2015; Rodon et al., 2013; Vanhaesebroeck et al.,
2011).

For example, specifically blocking the PI3’Kα isoform may result in an

increase in the expression or activity other PI3’Kinase isoforms, thus allowing
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signaling to continue. Due to this type of resistance, multiple isoform and pan class
PI3’Kinase inhibitors have been developed, such as Wortmannin and LY294002.
However, a major caveat is the toxic side effects associated with these types of
inhibitors. A third mechanism of adaptive resistance to PI3’Kinase inhibition is the
activation of other heterologous signaling cascades capable of activating the same
downstream signaling molecules activated by the PI3’Kinase pathway (Martin et
al., 2017).
LY294002: In 1994, a group led by Vlahos at Lilly Research Laboratories
(now Eli-Lilly), discovered a compound able to inhibit PI3’K enzymatic activity as
well as the activity of other proteins containing tyrosine kinase activity, such as
PDGFR, insulin receptor, and various oncogenes (v-src) (Vlahos et al., 1994). At
the time, it was known that PI3’Ks functioned to transfer phosphate groups to the
D3 position of PtdIns. However, the biological role of PI3’K or its products was still
unclear. The role of PI3’Ks in cellular proliferation was suggested due to the
contribution of PI(3,4,5)P3 in actin polymerization upon growth factor stimulation,
although it was not yet firmly established. To elucidate the definitive role of PI3’K
in cellular proliferation, Vlahos’s group suggested that inhibitors targeting the
enzymatic activity of PI3’K would be instrumental. Quercetin, a flavonoid, had
previously been described as an inhibitor of PI3’K activity in the micromolar range;
however, it was also shown to inhibit a broad range of protein kinases, and thus
was inadequate to elucidate the specific roles of PI3’K activity. Using quercetin as
a model compound, Vlahos et al synthesized numerous compounds and tested
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them for their ability to inhibit PI3’K activity.

2-(4-Morpholinyl)-8-phenyl-4H-l-

benzopyran-4 (LY294002) was discovered to be 2.7-fold more sensitive than
quercetin at inhibiting PI3’K activity (Vlahos et al., 1994). It is important to note
that the effective inhibitory concentration of LY294002 against PI3’K activity was
still in the micromolar range. LY294002 was also exceptionally more specific for
PI3’K activity, as the original studies failed to see any inhibitory effect of this
compound on EGFR, c-src, MAPK and other kinases known to be inhibited by
quercetin. Later studies showed that LY294002 functions as a competitive ATP
inhibitor that can selectively target Class I PI3’K and other members in the Class
IV PI3’K family (Workman et al., 2010).
Wortmannin: Although LY294002 was the first known inhibitor of PI3’K,
Wortmannin soon became known as the most potent inhibitor of PI3’Kinase
activity, with inhibition of PI3’Kinase occurring in the nanomolar range.
Wortmannin was first isolated from the bacterium Penicillium wortmanni in 1957
by Brian et al and was shown to have potent antibiotic properties against fungi over
bacteria (Brian et al., 1957). During the study, it was determined that Wortmannin
was highly unstable, with a half-life of less than 24 hours at 25°C, and later studies
would show that Wortmannin is even less stable under cell culture conditions .
In 1988, H.K. Abbas and C.J. Mirocha led a team determined to find the
hemorrhagic factor being secreted from the fungi Fusarium oxysporum that was
responsible for causing death in farm animals and humans in food producing areas
(Abbas and Mirocha, 1988). It was shown that different isolates contained different
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degrees of toxicity; therefore, they focused on isolating metabolites from Fusarium
oxysporum isolated in colder areas, as these metabolites seemed to be the most
toxic. An isolate collected from the arctic region in Norway was tested and named
H-1 due to its potent hemorrhagic ability (Powis et al., 1994). Further study using
mass spectrometry revealed that H-1 was analogous to Wortmannin (Abbas and
Mirocha, 1988; Vlahos et al., 1994).

This served as the first study isolating

Wortmannin from the genus Fusarium, and greatly increased interest in
Wortmannin’s mechanism of action.
Due to Wortmannin’s role in inhibiting respiratory burst (the rapid release of
reactive oxygen species from cells) and its ability to induce hemorrhagic
responses, in 1994 it was shown that Wortmannin inhibited the phosphorylation of
pleckstrin (Arcaro and Wymann, 1993; Baggiolini et al., 1987; Powis et al., 1994).
At this same time, it was discovered that increased PI(3,4,5)P3 levels
corresponded with increased respiratory burst. Therefore given that Wortmannin
inhibited respiratory burst, it was shown that Wortmannin inhibited PI(3,4,5)P3
formation by inhibiting PI3’K (Powis). By 1995, numerous off-target proteins were
shown to also be regulated by Wortmannin, including phospholipase A2, myosin
light chain kinase, mTOR, and DNA-PK (Ui et al., 1995). Despite these off-target
effects, Wortmannin is still utilized as a potent broad spectrum PI3’K inhibitor that
has improved stability over other inhibitors targeting the PI3’Kinase family of
enzymes (Kuete et al., 2015).
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Wortmannin exerts its effects by acting as a non-reversible covalent
inhibitor of PI3’K that functions by forming a covalent bond at the critical, conserved
lysine residue (Lys802) in the kinase active site (Wymann et al., 1996). Even
though Wortmannin is a broad spectrum PI3’K class inhibitor, it has a higher
inhibitory effect on Class I PI3’Ks. Wortmannin can also inhibit Class II PI3’Ks,
specifically PIK3C2B, but is less active against PIK3C2A (Domin et al., 1997).
Because of the off-targets effects of Wortmannin, the results of experiments
utilizing Wortmannin must be interpreted with caution. It is not appropriate to solely
implicate PI3’kinase enzymatic activity in data if other, non-PI3’Kinase molecules
are being inhibited (Traer et al., 2006). While it is known that PI3’K enzymes play
a key role in numerous cell signaling cascades, experiments using Wortmannin
must take into consideration that other proteins and pathways may contribute to
the results gathered following treatment with Wortmannin. Thus, other, more
selective PI3’Kinase inhibitors have since been developed that can be utilized to
understand more precisely the role that the PI3’Kinase family has in cell signaling
and disease.
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AKT
AKT, a protein kinase, was the first identified effector of the PI3’K signaling
cascade and is responsible for propagating signals to effect downstream cellular
pathways (Vara et al., 2004). In 1987 Stephen Staal isolated the proto-oncogene
(v-akt) from the AKT8 transforming retrovirus, containing oncogenic sequences
responsible for producing areas of malignant transformation in the thymus of mice
in the high leukemia AKR mouse model (Staal, 1987; Staal and Hartley, 1988). It
was not until 1991 that three independent research groups isolated and cloned the
human analog of v-akt, AKT1 (Bellacosa et al., 1991). It is now known that there
are three AKT isoforms: AKT1, AKT2,
and AKT3.
AKT structure and function
AKT is a 57 kDa protein that
functions by phosphorylating the serine
and threonine residues on substrates to
transduce

upstream

signals

into

downstream signal propagation. In 1991,
the group led by Woodgett and Coffer
found that AKT displayed high sequence
homology to protein kinase A (PKA) and
protein kinase C (PKC), therefore, AKT is
also termed protein kinase B (PKB)
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Figure 1.7 AKT Structure: A) AKT exists in a
closed, inactive conformation in the cytosol.
PH domain binding at the plasma membrane
results in an open active conformation. B)
Three AKT isoforms. Identification of major
domains, regions and regulatory
phosphorylation sites.

(Bellacosa et al., 1991; Coffer and Woodgett, 1991). This homology to PKC and
other kinases places the AKT isoforms in the AGC family of kinases (related to
AMP/ GMP kinase and PKC), which also contains proteins such as PDK1 and
SGK. The structure of the three AKT members is highly homologous, and each
isoform contains an amino terminal PH homology domain, an α-helical linker
region, a kinase domain, and a carboxyl terminal regulatory domain (Figure 1.7).
PH Domain
The PH domain is approximately 120 amino acids in length, and the binding
pocket within this domain forms hydrogen bonds with the available phosphate
groups of specific phosphatidylinositol (PIP) species. Binding of the PH domain
within proteins, to PIPs species, results in the cellular relocation of these proteins
to the inner leaflet of the plasma membrane. The PH domain of AKT binds with
similar affinity to PI(3,4)P2 and PI(3,4,5)P3 (Franke et al., 1997b; Klippel et al.,
1997). Under non-stimulated conditions, AKT resides in the cytosol in its inactive
conformation, where the PH domain adopts a closed conformation, preventing
PDK1 from phosphorylating AKT at the threonine 308 (Thr308) site. This PHblocking conformation has been termed the “PH in” conformation (Figure 1.7A).
Upon binding of the PH domain to specific PIPs at the cell surface, the PH domain
releases AKT from its inhibitory conformation and exposes the Thr308 site, known
as the “PH out” conformation (Figure 1.7A). Inner leaflet binding of AKT results in
moving AKT in close proximity to PDK1 due to PDK1’s own PH domain binding to
specific PIP species. PDK1 phosphorylation of Thr308 in the T-loop of the catalytic
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domain of AKT then results in its partial activation, and full activation of the AKT
enzyme is achieved through phosphorylation of the Serine 473 (Ser473) site in the
hydrophobic motif of the regulatory domain (Fresno Vara et al., 2004). Activating
mutations within the PH domain, such as the E17K mutation, result in constitutive
binding of AKT to the plasma membrane, leading to sustained downstream
signaling and hyper-activation of downstream signaling cascades.
α-linker region
The α-linker region of AKT is the least studied region of AKT. However, a
high degree of heterogeneity exists in this region between the AKT1, AKT2 and
AKT3 isoforms. The PH, kinase, and regulatory domains of the AKT isoforms are
highly homologous; therefore, the heterogeneity within the α-linker region may be
a mechanism of isoform specificity within the AKT family.

Supporting this

hypothesis, Toker’s group discovered that the α-linker region may act as a
“docking motif” to preferentially allow AKT1, rather than AKT2, to phosphorylate
paladin (protein involved in cell adhesion) in breast cancer cell lines (Franke et al.,
1997b). However, more studies must be conducted to determine how this region
is regulated and its involvement in signaling specificity amongst the AKT isoforms.
Catalytic/Kinase Domain
The catalytic domain (CD) is the centrally located domain in AKT that has
high sequence homology to the CD of the other AKT isoforms. At the core of the
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CD, within the T-loop, resides the Thr308 site. This site is phosphorylated by
PDK1, and phosphorylation at this site leads to the partial activation of AKT.
Regulatory Domain
The hydrophobic motif (HM) is a region within the C-terminal regulatory
domain that is a hallmark structure of the AGC family of kinases. Ser473 is located
within the HM and is a major regulatory phosphorylation site within the domain.
Phosphorylation at this site results in full activation of the AKT kinase, increasing
the number of substrates that AKT is able to phosphorylate.
AKT in Cell signaling
AKT is a signaling hub (Figure 1.8) that is implicated in numerous cellular
processes through direct and indirect interaction of AKT with signaling molecules
involved in cell growth, proliferation, and other processes. mTOR, GSK3B, BAD,
and FOXO3 are substrates that have been identified as directly regulated through
phosphorylation by AKT.

AKT-dependent phosphorylation of mTOR, when

associated with the mTORC2 complex, activates mTOR, resulting in the
phosphorylation of 4E-BP1 bound to eIF4E; this phosphorylation event releases
eIF4E to facilitate the initiation of cap-dependent translation and subsequent
increase in cell size. Phosphorylated mTOR also leads to the activation of S6K, a
ribosomal protein, which leads to increased protein synthesis. Activation of mTOR
by AKT can also regulate numerous other cellular processes depending up the
downstream signaling cascade that is activated; this highlights the complexity of
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AKT substrates. Due to AKTs involvement in numerous cellular processes, it is
predictable that dysregulated AKT activity is implicated in numerous pathologies
including diabetes, brain abnormalities, and cancer. In fact, it has been reported
that elevated levels of AKT activity is present in up to 50% of cancer (Vasudevan
and Garraway, 2011).

Figure 1.8 Kegg pathway of AKT signaling. AKT serves as a signaling hub in which proteins
can become activated or de-activated upon phosphorylation by AKT.
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AKT isoforms:
AKT1: AKT1 (Figure 1.7) is located on chromosome 14 (14q32) and is the
mostly widely studied of the AKT isoforms, displaying a wide tissue expression
pattern in humans (Zinda et al., 2001). Transgenic mouse studies determining the
effect of heterozygous and homozygous deletion of AKT1 demonstrated that AKT/-

mice weighed less than their non-transgenic littermates (Chen et al., 2001). The

subtle phenotype of AKT1-/- mice highlights the redundant or compensatory
mechanisms that exist between the AKT isoforms. In addition, while AKT1-/- mice
typically display subtle phenotypes, it was discovered that mice lacking AKT1 in
the mammary gland present with decreased mammary gland development during
pregnancy, resulting in lactation defects (Maroulakou et al., 2008). AKT1-/- mice
also tumor displayed reduced tumor formation

in the presence of PTEN

haplodeficiency , suggesting that AKT1 expression may be a contributing factor in
tumorigenesis (Chen et al., 2006). Canonical PI3’Kinase signaling identifies AKT1
as the predominant isoform eliciting signal propagation in many malignancies.
AKT1 is the most commonly mutated AKT isoform and has been implicated in
many human cancers including lung, ovarian, colon, endometrial, and invasive
breast cancer (Beaver et al., 2013).
AKT2: AKT2 (Figure 1.7) is located on chromosome 19 (19q13) and
displays a wide tissue expression pattern, with elevated expression found in tissue
responsive to insulin signaling, such as brown fat, skeletal muscle and the liver
tissue (Kim et al., 2000). AKT2-/- transgenic mouse studies revealed that AKT2
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plays a key role in insulin homeostasis; AKT2-/- mice present with diabetes-like
syndromes and display high fasting glucose levels and insulin resistance (Cho et
al., 2001). Further support that AKT2 regulates insulin signaling comes from colocalization studies done in HEK-293 cells revealing that AKT2 co-localizes with
mitochondria, supporting the idea that AKT2 functions in regulating glucose energy
metabolism (Santi and Lee, 2010). These data suggest that AKT2 has a nonredundant role that cannot be compensated for by AKT1 or AKT3 knockout.
Interestingly AKT1/2 knockout studies revealed that these transgenic mice were
postnatally lethal and displayed decreased body weight (Braccini et al., 2015).
AKT3: AKT3 (Figure 1.7) is located on chromosome 1 (1q44) and AKT3
protein is preferentially expressed in neuronal tissue (Easton et al., 2005).
Although AKT3 is the least studied of the AKT isoforms, functional studies
comparing AKT3 to AKT1 have identified isoform-specific functions of AKT3.
Studies utilizing AKT3 knockout mice demonstrated a developmental role for the
AKT3 isoform; although AKT3-/- mice were not embryonically lethal, maintained
normal body weight, and maintained normal homeostatic glucose levels, these
mice contained significantly smaller brains in both size and weight when compared
to WT mice and AKT1-/- mice (Easton et al., 2005).

Easton et al. demonstrated

that the brains of AKT3-/- mice had significantly reduced levels of phospho-S6, a
target of mTORC1 that regulates cell size. These results indicated that AKT3 is
required to maintain normal levels of phospho-S6 and the small brain sizes seen
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in AKT3-/- mice suggest that AKT3 influences mTOR-mediated maintenance of cell
size (Easton et al., 2005).
Using transgenic mice overexpressing AKT3 in cardiomyocytes, Taniyama
et al. demonstrated that AKT3 overexpression resulted in hypertrophic hearts,
which they determined to be maladaptive hypertrophy (Taniyama et al., 2005).
Data collected from human samples revealed that diseased hearts had
significantly higher expression of AKT3 protein compared to AKT1 and AKT2, and
the authors noted that little variability existed between the expression levels of
AKT1 and AKT2 between diseased and normal hearts. These data validated the
transgenic mice data and taken together it was concluded that AKT3 functions
through mTOR signaling to maintain normal cell size. They also concluded that
elevated levels of AKT3 contribute to the diseased state of human hearts
(Taniyama et al., 2005). AKT3 has also been implicated in the development of
malignant melanoma. A study by Stahl et al. showed that elevated levels of AKT3
coupled with decreased PTEN expression contributed to the aggressiveness of
malignant melanoma (Stahl et al., 2004). The results of this study, along with
others, suggest that AKT3-specific targeting could potentially be a good
therapeutic target in malignant melanoma. In addition, elevated AKT3 levels have
been linked to other human malignancies such as glioblastoma multiform,
androgen insensitive prostate cancer and ER- breast cancer (Nakatani et al.,
1999).
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It is generally accepted that the phosphorylation of the individual AKT
isoforms is responsible for regulating the activity of these kinases. However,
studies suggest that it is not the phosphorylation of AKT3 but rather the
overexpression of AKT3 that is governing its activity (Chin et al., 2014; Nakatani
et al., 1999; Taniyama et al., 2005; Turner et al., 2015). There have been many
studies aimed at understanding how elevated AKT3 expression contributes to the
aggressive phenotype found in many disorders, however, the determinants of the
increased expression of AKT3 has been limited. A study completed by Fieber et
al. demonstrated that the expression of AKT3 is indirectly regulated by growth
factor stimulation, specifically vascular endothelial growth factor (VEGF), through
VEGF mediated upregulation of the sphingosine-1-phosphate (S1P) receptor
Edg3/S1P1 (S1P3) in endothelial cells (Fieber et al., 2006). This group also
determined that the mechanism of AKT3 upregulation was due to stabilization of
AKT3 mRNA via stimulation with VEGF and S1P, and that this was governed in a
PI3’Kinase-dependent manner.
The role of AKT3 expression in triple negative breast cancer
Elevated expression of AKT3 has recently been identified in triple negative breast
cancer and has been linked to the aggressive phenotype of this disease. Using a
short hairpin RNA (shRNA) screen in a panel of TNBC cell lines with the goal of
detecting critical kinases to serve as molecular targets within the TNBC subtype,
Chin et al. found that AKT3 message was significantly elevated in a subset of triple
negative breast cancer cell lines and identified AKT3 as frequently amplified and
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overexpressed in breast cancer (Chin et al., 2014). It has been reported that
approximately 30% of triple negative breast cancers display elevated expression
of AKT3 mRNA and protein. Based upon their studies, Chin et al. concluded that
AKT3 contributes to the growth of TNBC and that specific targeting of AKT3 may
provide therapeutic benefit in the treatment of patients with TNBC.
The COXPRESdb database provides predicted functional relationships for
individual and co-expressed proteins; datamining for processes associated with
AKT3 expression predicts that AKT3 contributes to the regulation of tight junction
signaling, cell adhesion molecules, MAPK kinase signaling and other cellular
processes (Okamura et al., 2015). Cellular localization studies done in HEK-293
and 293-T cells showed that AKT3 was primarily localized to the nucleus and
nuclear membrane, while AKT1 resided in the cytoplasm and the nucleus, and
AKT2 co-localized with mitochondria; however, it is important to note that cellular
localization of each isoform is cell-type dependent (Santi and Lee, 2010). Due to
the significant role played by AKT3 in different cellular processes and disease
states, studies aimed at understanding AKT3 gene regulation have increased in
the last decade; however, the upstream signaling mechanisms by which AKT3 are
regulated has yet to be determined.
Therapeutic targeting of AKT:
Because of AKT’s role as a central hub of signal propagation, targeted drugs have
been designed to inhibit its activation and prevent the downstream signal
propagation of pathways contributing to tumor progression. The presence of
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phosphorylated AKT is often used as a readout of activated PI3’K signaling
(Fresno Vara et al., 2004; Hennessy et al., 2005). Therefore, the development of
AKT inhibitors as a mechanism of blocking downstream PI3’K signaling has been
major focus of research with the goal of creating targeted therapeutics designed
to specifically inhibit pathways contributing to the disease states in which aberrant
AKT activity has been implicated. ATP competitive and allosteric inhibitors are the
two main classes of drugs that have been designed to inhibit the activity of AKT.
ATP competitive inhibitors bind to the active site of the enzyme and compete with
ATP for binding. These molecules preferentially target the activated AKT enzyme.
Counterintuitively, these drugs are not able to inhibit AKT activity specifically,
rather, these compounds prevent activated AKT from phosphorylating its
substrates. The caveat to this class of inhibitors is their inability to specifically
target the AKT isoenzymes due to high homology of the ATP binding pocket with
the AGC kinase family. First generation competitive inhibitors, due to the wide
range of off-target effects, resulted in severe adverse events in patients. This led
to the development of second generation competitive inhibitors designed with
higher specificity for the AKT isoforms over other AGC kinase family members
(Freeman-Cook et al., 2010).
Preclinical data gathered with the second-generation inhibitors demonstrated that
these drugs successfully attenuated AKT signaling. Phase I clinical trial data
indicated that the use of AKT-specific, competitive ATP inhibitors, results in
antitumor efficacy; however, patient toxicity remains a problem. A Phase I clinical
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trial with the second-generation competitive inhibitor, Ipatasertib (GDC0068), in
patients with solid tumors revealed that this molecule was generally well tolerated
with low frequencies of high grade adverse events (Saura et al., 2017).
Retrospective analysis demonstrated that patients with PIK3CA mutations
generally tolerated GDC0068 better than patients without PIK3CA mutations. This
is a significant finding due to the lack of patient stratification that typically occurs in
Phase 1 clinical trials of targeted inhibitors. By identifying the patient cohort that
is most likely to respond to treatment with a specific inhibitor, greater efficacy would
be achieved at tolerable doses, leading to the advancement of drugs through
clinical trials and subsequent use in the clinic.
Allosteric AKT inhibitors function by interacting with the PH domain of the
inactivated form of AKT.

Binding of the allosteric inhibitor prevents the

translocation of AKT from the cytosol to cellular membranes, preventing the
phosphorylation and activation of the kinase. MK2206 is an allosteric AKT inhibitor
that has been used in numerous preclinical studies to understand the complex role
that AKT plays within the cells. Studies using MK2206 have shown that the drug
is less potent at inhibiting the activity of AKT3 compared to that of AKT1 and AKT2
(Yan, 2009).

Studies have also shown that in cell lines with elevated AKT3

expression treated with MK2206 and assessed for AKT phosphorylation, MK2206
fails to attenuate total AKT phosphorylation (Stottrup et al., 2016). These studies
demonstrated that higher concentrations of MK2206 are needed to inhibit AKT3
phosphorylation compared to the concentration needed to inhibit AKT1 and AKT2
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activity. Taken together, these data demonstrate the decreased specificity that
MK2206 has for the AKT3 isoform (Yan, 2009).
Cell lines harboring the E17K mutation, which results in a constitutively active
membrane bound AKT, displayed refractory responses to inhibition of AKT
phosphorylation by MK2206 (Huck and Mochalkin, 2017).

The inability to

effectively inhibit this mutant form of AKT may be since MK2206 specifically targets
the inactive conformation of the kinase. In recent years, efforts have been focused
on generating second generation allosteric inhibitors with higher specificity for
mutant forms of AKT (Brown and Banerji, 2017).
MK2206 remains the most extensively studied allosteric AKT inhibitor, having been
involved in over 30 Phase II clinical trial studies (ClinicalTrials.gov, 2018). Despite
numerous clinical trials designed around MK2206 as a single agent or in
combination with chemotherapeutics and other targeted inhibitors, the results from
these trials have been bleak. MK2206 has been shown to have a high toxicity
profile and patient efficacy has not been exhibited. However, the parameters used
for the recruitment of patients into clinical trials involving MK2206 have been based
upon different conditions: a) patients with advanced disease states and/or
recurrence, b) efficacy of MK2206 with other therapeutics, or c) speculative trails
with patients that have been resistant to chemotherapy. Unfortunately, these
clinical trials have not been designed with the biology of the patient tumor in mind.
Given that MK2206 has decreased efficacy for AKT3 and AKT harboring E17K
mutations, patients with these molecular phenotypes most likely will not respond
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to treatment with MK2206. Therefore, these patients should be excluded from
enrollment into clinical trials with this inhibitor. If the patients that would benefit
from the addition of MK2206 to their treatment regimen are not actually being
targeted, then the window of opportunity to determine the true efficacy of the drug
is being missed and patients will continue to die due to inappropriately treated
disease. This highlights the significance of understanding the basic biology of the
signaling driving tumor progression in order that accurate and effective treatment
strategies will be administered to patients with the goal of improving overall
survival.
Significance of AKT3 in breast cancer: The various AKT isoforms play many roles
in the context of cell signaling as well as breast cancer biology (Manning and
Cantley, 2007; Vasudevan and Garraway, 2011). While the AKT1 and AKT2
isoforms have been the most extensively studied and implicated in contributing to
numerous aspects of breast cancer biology, AKT3 also has a significant role in this
field of research (Chin et al., 2014; Mure et al., 2010; Nakatani et al., 1999).
Interestingly, AKT3 is the most commonly amplified AKT isoform (18.96% of nonoverlapped samples from 9 cohorts of patients, 3180 total patient samples) while
AKT1 and AKT2 are only amplified in 1.19% and 1.07% of patients respectively.
Based upon data gathered from cBioPortal, AKT1 is the most commonly mutated
AKT isoform (33.6% compared to 0.49% and 0.3% for AKT2 and AKT3,
respectively) within the 12 cohorts of patient samples (Klonowska et al., 2016).
Despite the high prevalence of AKT3 expression in breast cancer, studies have
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not focused on the regulation of this specific AKT isoform. Studies involving AKT3
have been limited to AKT3’s phenotypic role in cancer progression.

Isoform

specific signaling exists due to the vastly different phenotypes that are present as
a result of individual AKT isoform manipulation. While extensive studies have
looked at the role that Class I PI3’Ks play in the activation of AKT1, the mechanism
of activation of AKT3 in relation to PI3’K signaling has yet to be determined. This
dissertation provides the first evidence that AKT3 is regulated only in part through
canonical class I PI3’Kinase signaling and demonstrates that class II PI3’Kinases,
specifically PI3K-C2β, is a potent regulator of AKT3 activation. The implications
of this research are that AKT3 has been implicated driver of tumorigenesis and
cancer progression in numerous cancers including TNBC, glioblastoma and
melanoma. Currently, there are no specific AKT3 inhibitors or PI3K-C2β-specific
inhibitors being utilized in the clinical setting. Our data directly identifies PI3KC2β as a major regulator of AKT3 activation; therefore, solely targeting the class I
PI3’Kinase enzymes will be insufficient to block AKT activation in the subset basal
breast cancer patients.

Further, patients presenting with melanoma and

glioblastoma often present with decreased or loss of PTEN expression in addition
to elevated AKT3 levels (Madhunapantula and Robertson, 2009; Turner et al.,
2015). Although the data presented in this dissertation specifically focuses on
PTEN-null basal breast cancer cell lines, the lack of therapeutic treatment
strategies for melanoma and glioblastoma patients are similar to patients
presenting with basal breast cancer. By identifying that AKT3 expression is
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regulated by class I and class II PI3’Kinases, targeted therapeutics can readily be
designed using drugs that are already used in the clinical setting. Further research
on the mechanism of AKT3 activation will confirm these findings.
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Chapter 2:
Materials and Methods
2.1 Cell lines and Cell Culture:
SUM-149 cells were maintained in Ham’s F-12 medium with 5% fetal bovine
serum, 5 µg/mL insulin, 1 µg/mL hydrocortisone, 25 µg/mL gentamicin, and 2.5
µg/mL fungizone (5%IH). Control vector and PTEN expression vector infected
SUM-149 and SUM-229 cells were maintained in 5%IH containing 10 µg/mL
Blasticidin to maintain selection. MCF10A cells were maintained in SFIH (Ham’s
F-12 with 1 µg/mL hydrocortisone, 5 µg/mL insulin, 1 mg/mL bovine serum
albumin, 10 mM HEPES, 5 mM ethanolamine, 5 mg/mL transferrin, 10 nM
triiodothyronine, 50 nM sodium selenite. HCC-38, MDA-MB-436, MDA-MB-468,
HCC-1937 cell lines were maintained in DMEM with 10% fetal bovine serum (10%
DMEM), 25 µg/mL gentamicin, and 2.5 µg/mL fungizone. All cells were maintained
in a humidified incubator at 37 °C and 10% CO2.
2.2 Reagents:
The pan class I PI3’Kinase inhibitor BKM120, PI3Kα specific inhibitor A66, PI3Kβ
specific inhibitor GSK2636771, class III PI3’Kinase inhibitor SAR405, pan class
PI3’Kinase inhibitor GDC0032, allosteric AKT inhibitor MK2206, pan mTOR
inhibitor KU0063794 and EGFR inhibitor Gefitinib were all purchased from
Selleckchem. The non-specific PI3’Kinase inhibitor wortmannin was purchased
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from EMD Millipore. Antibodies against PTEN (Cat #9188), anti-rabbit phosphoAKT (Ser473)(Cat #4060), anti-rabbit pan-AKT (Cat #4691), anti-mouse phosphoAKT (Ser473)(Cat #12694), anti-mouse pan-AKT (Cat #2920), anti-rabbit AKT1
(Cat #2938) and anti-rabbit AKT3 (Cat #14982) were purchased from Cell
Signaling. The anti-mouse B-actin antibody (Cat #A5441) was purchased from
Sigma-Aldrich. The SUM-149 cell line was established by my mentor Dr. Stephen
P. Ethier (Hoffmeyer et al., 2005). The HCC-38, MDA-MB-436, MDA-MB-468,
HCC-1937 cell lines were purchased from ATCC. The MCF10A cells were a gift
from Dr. Herb Soule at the Michigan Cancer Foundation. Primers used for RT-PCR
were ordered from IDT. Pierce™ ECL Western Blotting Substrate was purchased
from ThermoFisher Scientific (Cat. #32106). Restriction enzymes Xhol (Cat
#R0146S) and AflII (Cat #R0520S) were purchased from New England
Biosystems.
2.3 PTEN expression ORF vectors using Gateway Cloning
Entry Vector (pENTR221) plasmids containing the full-length PTEN ORF
sequence w/ a stop codon was obtained from Open Biosystems as a part of the
ORFeome collaboration (Invitrogen). Glycerol stocks were streak isolated and
cultured overnight. Plasmid DNA isolated from bacterial growths using the
Promega PureYeild Plasma Midi Prep System (Promega Cat. #A2492). The LR
recombination reaction was performed to shuttle the pENTR221_PTEN vector into
the Destination vector (pLenti6.3/V5-DESYT Gateway Vector), to create the
expression vector. Briefly, the entry clone (50-150 ng), destination vector (150 ng),
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TE buffer, and LR Clonase II were co-incubated at 25°C for 1 hr, after which 1 µL
of proteinase K (used to remove clonase and terminate LR reaction) is added to
the solution and incubated at 37°C for 10 min. Upon completion of LR reaction,
One Shot Stbl3 Competent E. coli cells were transformed with 2-3 µl of the LR
reaction. Competent cell and LR reaction mixture were placed on ice for 30 min.
Next, the cells were heat shocked for 30 sec at 42°C and returned to the ice for 2
min. Competent-LR reaction mixture was added to a sterile 15 mL conical
containing 1 mL of LB medium (pre-warmed). Tubes were capped tightly and
shaken horizontally for 1 hr at 37°C at 222 rpm. Transformation mix (100 µL) was
spread onto pre-warmed LB plates containing 100 µg/mL Ampicillin and incubated
overnight at 37°C. 10-20 ampicillin-resistant colonies were isolated from the
transformation and cultured overnight. Plasmid DNA was isolated using Invitrogen
Pure Link Quick Plasmid MiniPrep kit (Invitrogen Cat. # K2100-11) and restriction
digested to confirm insert length. Selected clones were cultured, and DNA was
isolated using the Promega PureYeild Plasma Midi Prep System. To produce
lentivirus from PTEN expression constructs, human embryonic kidney (HEK293)
cells were grown to 75% confluence and were transfected in 10% DMEM (without
antibiotics) with 3 µg of the construct and MISSION Lentiviral packaging mix
(Sigma, shp-001) using Lipofectamine 2000 Transfection reagent (Thermofisher11668019) according to the manufacturer's protocol. Cells were incubated for 24hr
at 37°C, at which time media was changed to 10% DMEM (without antibiotics).
The virus was harvested 48 and 72hrs post infection, centrifuged at 1500 rpm for
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5 min and filtered through a 0.45-micron PES filter. Recipient cells were seeded at
1x106 cells per 10 cm dish, treated with 8ug/mL polybrene and infected. Cells were
incubated at 37°C for 12 hr and new media was added. After 3 days, 1 µg/mL
puromycin was added to select for cells expressing the shRNA constructs. Cells
were maintained for 2 weeks before functional assays were performed.
2.4 Lenti-AKT1, AKT2, AKT3 shRNA infection
Knockdown of the individual AKT isoforms was achieved using the MISSION TRC
human shRNA clone sets listed below (obtained using the MUSC shRNA
Technology Shared Resource which utilizes The RNAi Consortium’s (TRC)
genome-wide lentiviral mouse and human libraries):
shAKT1:
*TRCN 39797:

CCGGCGCGTGACCATGAACGAGTTTCTCGAGAAACTCGTTCATGGTC
ACGCGTTTTTG

TRCN 10162:

CCGGGGACAAGGACGGGCACATTAACTCGAGTTAATGTGCCCGTCCT
TGTCCTTTTT

shAKT2:
*TRCN 265834:

CCGGCGGCTCCTTCATTGGGTACAACTCGAGTTGTACCCAATGAAGG
AGCCGTTTTTG

TRCN 255917:

CCGGAGGACCTTCCACGTGGATTCTCTCGAGAGAATCCACGTGGAAG
GTCCTTTTTTG

shAKT3:
*TRCN 197265:

CCGGGATGTGGATTTACCTTACCTTATCCCCTCGAGGGGATAAGGTA
AATCCACATCTTTTTTG

TRCN 196521:

CCGGGTAGTCCAACTTCACAAATTGCTCGAGCAATTTGTGAAGTTGGA
CTACTTTTTTG
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To produce lentivirus from shRNA constructs, human embryonic kidney (HEK293)
cells were grown to 75% confluence and were transfected in 10% DMEM (without
antibiotics) with 3 µg of the construct and MISSION Lentiviral packaging mix
(Sigma, shp-001) using Lipofectamine 2000 Transfection reagent (ThermofisherCat #11668019) according to the manufacturer's protocol. Cells were incubated
for 24hr at 37°C, at which time media was changed to 10% DMEM (without
antibiotics). The virus was harvested 48 and 72hrs post infection, centrifuged at
1500 rpm for 5 min and filtered through a 0.45-micron PES filter. Recipient cells
were seeded at 1x106 cells per 10 cm dish, treated with 8 µg/mL polybrene and
infected. Cells were incubated at 37°C for 12 hr and new media was added. After
3 days, 1 µg/mL puromycin was added to select for cells expressing the shRNA
constructs. Cells were maintained for 2 weeks before functional assays were
performed. Efficiency of knockdown was assessed via western blot analysis.
Further experiments were completed using the constructs that have been
asterisked.
2.5 RT-PCR
MCF-10A, HCC-38, SUM-149, MDA-MB-436, MDA-MB-468 and HCC-1937 cell
lines were grown to 90% confluency; RNA was isolated using an RNeasy kit from
Qiagen (Cat. #74106) and reverse-transcribed into cDNA using the iScript cDNA
Synthesis Kit (BIO-RAD Cat. #1708890). Following cDNA conversion, RT-PCR
reactions were performed in 96-well white-walled plates using FastStart Universal
SYBR Green Master Mix (Roche Cat. #4913850001). Reactions were performed
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on an Eppendorf Mastercycler Realplex2 under the following parameters: 1 cycle
for 10 min at 95°C, then 40 cycles of 95°C for 15 sec and 53°C for 30 sec. Primer
sets were designed and synthesized by IDP. Primer sets were:
AKT1:
Forward- ’GATCTTCATGGCGTAGTAGCG3’
Reverse- 5’GCTGAAGAGATGGAGGTGTC3’
AKT2:
Forward- ’GATCTTCATGGCGTAGTAGCG3’
Reverse- 5’AAGGCACGGGCTAAAGTG3’
AKT3:
Forward-5’CTATGAATGAGCCATCTGTCTT3’
Reverse- 5’CATGAGCGATGTTACCATTGTG3’

2.6 Colony-Forming assay
For colony forming assays, SUM-149 cells were seeded at clonal density (1x103
cells) in triplicate in 6-well plates and allowed to attach overnight. Cells were
treated with constant exposure to the drug for 72 hr, after which time, media was
replaced, and cells were unmoved until control wells reached a size of ~50-100
cells per colony (approximately 7 days). For staining, colonies were fixed with 1
mL/well 3.7% paraformaldehyde for 20 min at RT. Colonies were stained with 1
mL/well 0.2% crystal violet for 15 min at RT. The residual stain was removed using
dH20.

Colony counts were generated using the GelCount System (Oxford

Optronix).
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2.7 Western Blotting
Cells were plated and grown to 75% confluency in the presence of serum. Where
indicated, the cells were treated with 1.0 µM BKM120, 1.0 µM or 3 µM A66, 1.0
µM GSK2636, 1.0 µM MK2206, 1.0 µM KU0063794, 1.0 µM Gefitinib, 1.0 µM or 3
µM GDC0032, 50 nM or 500 nM Wortmannin for 2 hr. Cells were then lysed in
Ripa buffer (Sigma-Aldrich, Cat #R0278) containing 50 mM Tris (pH 8.0), 1.0%
IGEPAL CA-630, 0.5% Sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM
PMSF, 1X Protease Inhibitor cocktail (Calbiochem, 539131) and 1x phosphatase
inhibitor cocktail (PhosStop Cat #4906845001). Protein concentrations were
measured by Bradford assay (Bio-Rad). Laemmli sample buffer was added to the
lysates and the samples were boiled for 5 min before being separated by
electrophoresis on SDS-polyacrylamide gels (Bio-Rad). After transferring the
proteins to polyvinylidene difluoride (PVDF) membranes using the Trans-Blot
Turbo System (Bio-Rad) blots were probed overnight at 4 °C with the indicated
antibodies: PTEN (1:1000; Cell Signaling #9188), AKT Ser473 (1:1000; Cell
Signaling #4060), pan-AKT (1:1000; Cell Signaling #4691), β-actin (1:5000; Sigma
Aldrich #A5441), AKT1 (1:1000; Cell Signaling #2938) and AKT3 (1:1000; Cell
Signaling #14982).
2.8 Immunoprecipitation of AKT1 and AKT3.
Cells were plated and grown to 75% confluency in the presence of serum. Where
indicated, the cells were treated with 1.0 µM BKM120, 1.0 µM or 3 µM A66, 1.0
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µM GSK2636, 1.0 µM MK2206, 1.0 µM KU0063794, 1.0 µM Gefitinib, 1.0 µM or 3
µM GDC0032 ,50 nM or 500 nM Wortmannin for 2 hr. Cells were then lysed in
Ripa buffer (Sigma-Aldrich, Cat #R0278) containing 50mM Tris (pH 8.0), 1.0%
IGEPAL CA-630, 0.5% Sodium deoxycholate, 0.1% SDS, 150mM NaCl, 1 mM
PMSF, 1X Protease Inhibitor cocktail (Calbiochem, Cat #539131) and 1x
phosphatase
concentrations

inhibitor

cocktail

were

measured

(PhosStop
by

Cat

Bradford

#4906845001).
assay

Protein

(Bio-Rad).

For

immunoprecipitation of AKT1 and AKT3, 400 µg of whole cell lysate was incubated
with either anti-rabbit AKT1 (1:100; Cell Signaling Cat. #2938) or anti-rabbit AKT3
(1:50; Cell Signaling Cat. #14982).
2.9 Densitometry analysis of western bands
Densitometry was done using the Odyssey Fc Imaging System by LI-Cor
Biosciences. After overnight incubation with primary antibody (Section 2.7 for
specific primary antibody concentrations), PVDF membranes were incubated with
secondary antibodies (1:7500) labeled with horseradish peroxidase (HRP) for 1 hr
at RT. Blots were washed three times with TBST pH 7.5 and then incubated with
Pierce ECL chemiluminescent substrate (per the manufacturer's instruction) for 2
min. Western blots were quantitatively analyzed using the Odyssey FC Imaging
System. Arbitrary expression measurement units were obtained by the Odyssey
FC Imaging System for the protein bands of interest, and the values were saved
into a zip file. Blots were then re-incubated overnight with primary antibody
targeting β-actin (1:5000). Again, blots were washed, incubated with the
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appropriate secondary antibody followed by incubation with the ECL reagent. The
expression units gathered from the b-actin bands were used for normalization of
target interest band intensity. Bar graphs were generated for a graphical
representation of the western blot data.
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Chapter 3:
Results
Pharmacological inhibition of PI3'Kinase pathway mediators reveals varying
degrees of PI3'Kinase pathway-mediated AKT activity
Previous studies from our lab revealed that the SUM-149 cell line is PTENnull, overexpresses EGFR, has constitutive AKT phosphorylation and is
characterized as a basal-like triple negative breast cancer cell line. Due to PTEN’s
role as a direct negative regulator of PI3’Kinase enzymatic activity that leads to
activation of AKT, it is not surprising that the PTEN-null SUM-149 cell line displays
elevated AKT phosphorylation compared to the PTEN WT MCF-10A cell line
(Kappler et al., 2015). Kappler et al. also demonstrated that AKT phosphorylation
is elevated in the MDA-MB-468 cell line compared to the MCF-10A cell line a nontransformed spontaneously immortalized human mammary epithelial cell line with
a basal gene expression profile (Debnath et al., 2003; Keller et al., 2010).

The

MDA-MB-468 cell line is also classified as a basal-like PTEN-null triple negative
breast cancer cell line. Like SUM-149 cells, these cells also overexpress EGFR;
however, EGFR overexpression in the MDA-MB-468 cell line is due to EGFR gene
amplification.
For these studies, we also utilized the PTEN-null, p53 mutant, basal-like
breast cancer cell lines HCC-38, MDA-MB-436 and HCC-1937. This panel of
breast cancer cell lines served as our model system to study the canonical
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PI3’Kinase pathway in PTEN-null cell lines displaying constitutively elevated levels
of AKT phosphorylation. We hypothesized that pharmacological inhibition of the
key PI3’Kinase pathway mediators would effectively inhibit AKT phosphorylation
in the cell line panel. MCF-10A, HCC-38, SUM-149, MDA-MB-436, MDA-MB-468
and HCC-1937 cell lines were treated with 1 µM BKM120 (pan-class I PI3’Kinase
inhibitor), 1 µM MK2206 (allosteric AKT inhibitor) or 1 µM KU0063794 (pan-mTOR
inhibitor) for 2 hours. Cell lysates were harvested and AKT phosphorylation was
assessed by western blot (Figure 3.2). MCF-10A cells were included as a control.
The schematic in Figure 3.2 is an abridged representation of the complexity
of the PI3’Kinase signaling cascade; however, this figure plainly demonstrates
where key pathway mediators are located within the signal transduction pathway
and the point of attack for BKM120, MK2206 and KU0063794. Class I PI3’Kinases
drive the canonical PI3’Kinase/AKT signaling pathway through their production of
PtdIns (3,4,5) P3 (Altomare and Testa, 2005; Chang et al., 2003; Hennessy et al.,
2005); these second messengers serve as docking sites for AKT and PDK1 at the
inner membrane.

Membrane localization of AKT allows it to become

phosphorylated by PDK1 and subsequently fully activated by PKD2 (generally
recognized as the mTORC2 complex) at the Ser473 site (Fresno Vara et al., 2004).
Therefore, inhibition of class I PI3’Kinase enzymatic activity (BKM120) or inhibition
of mTORC2 activity (KU0063794) should effectively block AKT phosphorylation.
However, the data in Figure 3.1 shows that not all cell lines treated with
these inhibitors respond in the same manner; the HCC-1937 cell line exhibited the
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greatest reduction of AKT phosphorylation in the presence of PI3’Kinase/AKT
inhibitors, while the MCF-10A, HCC-38, SUM-149, MDA-MB-436 and MDA-MB468 cell lines all displayed varying degrees of AKT inhibition in response to panclass I PI3’Kinase inhibition (BKM) and pan-mTOR inhibition (KU). These results
indicate that the PI3’Kinase signaling pathway is not operating in a canonical
manner in most of the basal breast cancer cell lines tested. This suggests that AKT
phosphorylation in large subset of basal breast cancers is not regulated solely by
canonical PI3’Kinase signaling. The inability of mTOR inhibition to block AKT
phosphorylation in the MDA-MB-468 cell line could be expected given data
produced by Lee et al.; these authors demonstrated that the PDK2 responsible for
phosphorylating AKT at the Ser473 site in the MDA-MB-468 cell line was integrinlinked kinase (ILK), rather than the canonical mTORC2 complex (Lee et al., 2013).
However, the most striking result in Figure 3.1 was the inability of MK2206, a direct
allosteric inhibitor of AKT, to completely block AKT phosphorylation in the SUM149 and MDA-MB-436 cell lines, indicating that AKT phosphorylation in these cells
is resistant to MK2206.
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Figure 3.1 Inhibition of the PI3’Kinase pathway by BKM120, MK2206 and
KU0063794 is variable within the panel of basal-like triple negative breast
cancer cell lines

Figure 3.1 MCF-10A, HCC-38, SUM-149, MDA-MB-436, MDA-MB-468 and HCC-1937
cells were grown to 80% confluency and treated with BKM120, MK2206, KU0063794 at
1 µM for 2 hr and inhibition of PI3’Kinase activity was assessed via western blot.
Immunoblot analysis of the whole cell lysates indicate the efficiency of PI3’kinase
inhibition as assessed by AKT phosphorylation. PI3’Kinase inhibition was greatest in
the MCF-10A, HCC-38, MDA-MB-468 and HCC-1937 cell lines.
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Figure 3.2 Schematic representation of the Canonical class I PI3’Kinase/AKT signaling cascade
with emphasis on the specific targets of BKM120, MK2206 and KU0063794

Assessment of AKT3 gene and protein expression in a panel of PTEN-null
basal breast cancer cell lines
The finding that MK2206 failed to abrogate AKT phosphorylation in two of
the cells lines prompted us to investigate the mechanism that might be responsible.
There are three isoforms of AKT, and studies have shown that MK2206 is less
effective at inhibiting the activity of AKT3 compared to AKT1 and AKT2, with a half
maximal inhibitory concentration (IC50) approximately 8-fold higher for AKT3 than
AKT1 or AKT2 (Yan, 2009). Moreover, Stottrup et al. demonstrated that elevated
levels of AKT3 can confer resistance to MK2206 (Stottrup et al., 2016). Therefore,
based upon this information and our data that indicated that AKT phosphorylation
in the SUM-149 and MDA-MB-436 cell lines is resistant to treatment with MK2206,
we hypothesized that the resistance of these cells to MK2206 is due to the
presence of elevated levels of AKT3. To test this hypothesis, total RNA was
isolated from MCF-10A, HCC-38, SUM-149, MDA-MB-436, MDA-MB-468 and
HCC-1937 cells to assess the expression of the AKT isoforms by RT-PCR. The
data in Figure 3.3A shows that the SUM-149 and MDA-MB-436 cell lines not only
have the highest levels of AKT3 gene expression in the cell line panel, but are also
the only cell lines in which AKT3 gene expression is higher than AKT1 and AKT2.
To confirm and extend this result, western blot analysis was performed to evaluate
AKT1 and AKT3 protein levels in the cell line panel (Figure 3.3B). In agreement
with the gene expression data in Figure 3.3A the SUM-149 and MDA-MB-436 cell
lines displayed the highest expression of AKT3 protein. To better visualize the
relative protein expression of AKT3 in the cell line panel, densitometry of the
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western blot data (Figure 3.4B) was used to normalize the protein expression of
AKT3 in the cell line panel to the expression of AKT3 in the MCF-10A cell line. The
densitometry revealed that the SUM-149 and MDA-MB-436 cell lines were the only
cell lines in the panel with AKT3 expression levels higher than that of the MCF10A cell line, indicating that the residual AKT phosphorylation following treatment
with the allosteric AKT inhibitor in the SUM-149 and MDA-MB-436 cell lines is due
to the elevated expression of AKT3 protein in these cell lines.
Interestingly, our data revealed that the HCC-38 cell line lacks gene (Figure
3.3A) and protein expression of AKT3 (Figure 3.3B), indicating that the HCC-38
cell line is an AKT3-null cell line. Data mining of the HCC-38 cell line in the BroadNovartis Cancer Cell Line Encyclopedia database failed to indicate any AKT3
mutations in this cell line, thus, to our knowledge, our study is the first to reveal
that the HCC-38 cell line is AKT3-null, although the mechanism of AKT3 loss in
this cell line is not fully understood.
Elevated AKT3 expression requires higher concentrations of MK2206 to
inhibit AKT phosphorylation in AKT3-overexpressing cell lines
The IC50 of MK2206 for AKT3 is higher than that of AKT1 and AKT2 (8.1fold and 5.4-fold higher, respectively). Because the SUM-149 and MDA-MB-436
cell lines displayed residual AKT phosphorylation when treated with MK2206 and
have the highest expression of AKT3 in the cell line panel, we hypothesized that
higher concentrations of MK2206 would be needed to inhibit AKT phosphorylation
in these cell lines. To test this hypothesis, we treated the cell line panel with 1 µM,
3 µM and 5 µM MK2206 for 2 hrs, and assessed AKT phosphorylation by Western
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blot.

As shown in Figure 3.3, 1 µM MK2206 dramatically reduced AKT

phosphorylation in the MCF-10A (Figure 3.4A), HCC-38 (Figure 3. 4B), MDA-MB468 (Figure 3.4E), and HCC-1937 (Figure 3.4F) cell lines; however, 3 µM and 5
µM of MK2206 were needed to dramatically reduce AKT phosphorylation in the
MDA-MB-436 (Figure 3.4D) and SUM-149 (Figure 3.4C) cell lines, respectively.
The higher concentration of MK2206 needed to effectively reduce AKT
phosphorylation in the SUM-149 cells compared to the MDA-MB-436 cells can
likely be attributed to the higher expression of AKT3 in the SUM-149 cell lines
(Figure 3.4B). Taken together, we conclude that elevated expression of AKT3 the
SUM-149 and MDA-MB-436 cell lines is responsible for the resistance of AKT
phosphorylation to MK2206.
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Figure 3.3 AKT3 mRNA and protein expression is elevated in the SUM-149
and MDA-MB-436 cell lines

Figure 3.3 A) Relative mRNA expression by RT-PCR of AKT1, AKT2, and AKT3 in the
MCF-10A, HCC38, SUM-149, MDA-MB-436, MDA-MB-468 and HCC-1937 cell lines.
B) Western blot showing AKT1, AKT3 and total AKT levels in the panel of cells. Bar
graph represents densitometry of AKT3 expression within the panel of cells normalized
to the level of AKT3 in the MCF-10A cell line. Error bars represent the range of the data
of two replicates
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Figure 3.4 Higher doses of MK2206 are needed to inhibit AKT
phosphorylation in the SUM-149 and MDA-MB-436 cell lines

Figure 3.4 A) MCF-10A B) HCC-38 C) SUM-149 D) MDA-MB-436 E) MDA-MB-468 and F) HCC1937 cell lines were treated with MK2206 (1 µm, 3 µM, or 5 µM) for 2 hr and AKT phosphorylation
was assessed by western blot.
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Elevated AKT3 protein expression in the SUM-149 cell line contributes to the
resistance of AKT phosphorylation to PI3’Kinase pathway inhibition
Previous studies have shown that elevated expression of AKT3 contributes
to the progression of glioma, melanoma, and triple negative breast cancer (Chin
et al., 2014; Stahl et al., 2004; Turner et al., 2015). We hypothesized that AKT3
expression contributes to the resistance of AKT phosphorylation in the SUM-149
cell line to inhibition of PI3’Kinase pathway mediators. To test this hypothesis,
SUM-149 cells were stably infected with AKT1, AKT2, and AKT3 shRNA lentiviral
vectors containing constructs specific to achieve AKT isoform-specific knockdown.
The data in Figure 3.5A shows that effective and specific knockdown of each AKT
isoform was accomplished in the SUM-149 cell line. The cells were then treated
with 1 µM BKM120, MK2206 and KU0063794, for 2 hr and assessed for AKT
phosphorylation by western blot.
Knockdown of AKT3 in the SUM-149 cell line resulted in the greatest
sensitization of AKT phosphorylation to inhibition of PI3’Kinase pathway mediators
(Figure 3.5B). Taken together, these data indicate that elevated AKT3 expression
contributes not only to the resistance of cells to MK2206, but also contributes to
the resistance of AKT phosphorylation to inhibition of canonical PI3’Kinase
pathway mediators.
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Figure 3.5 Specific knockdown of AKT3 sensitizes AKT phosphorylation to
inhibition by PI3’Kinase pathway inhibitors

Figure 3.5 A) SUM-149 cells were stably infected with shRNA lentiviral expression constructs
targeting AKT1, AKT2 and AKT3. Levels of AKT1, AKT2 and AKT3 protein were measured by
western blot following knockdown. B) SUM-149 cells stably infected with shLacZ, AKT1, AKT2 or
AKT3 lentiviral expression constructs were grown to 90% confluency and treated with BKM120 (1
µM), MK2206 (1 µM) or KU0063794 (1 µM) for 2 hr. AKT phosphorylation in whole cell lysates
after treatment was assessed by western blot.
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Differential response of AKT1 and AKT3 phosphorylation following inhibition
of PI3’Kinase pathway mediators
Because AKT3 expression mediates the resistance of the SUM-149 cells to
inhibition of PI3’Kinase pathway components, we wanted to assess the response
of AKT3-specific phosphorylation to inhibition of PI3’Kinase pathway mediators
compared to the response of AKT1-specific phosphorylation. We hypothesized
canonical PI3’Kinase signaling is governing the activation of AKT1 and not AKT3.
To test this hypothesis, SUM-149 (Figure 3.6A), MDA-MB-436 (Figure 3.6B) and
HCC-1937 (Figure 3.6C) cell lines cells were treated with 1 µM BKM120 (pan class
I Pi3’Kinase inhibitor), 1 µM or 5 µM MK2206 (allosteric AKT inhibitor), 1 µM
KU0063794 (pan mTOR inhibitor), 50 nM Wortmannin (pan class PI3’Kinase
inhibitor) or 1 µM Gefitinib (EGFR inhibitor) for 2 hr. Cells were lysed and AKT1
and AKT3 were immunoprecipitated and assessed for phosphorylation by Western
blot. The HCC-1937 cell line was included in these experiments to serve as a
control cell line; these cells are PTEN-null, has constitutive AKT phosphorylation
but the HCC-1937 cells have normal levels of AKT3 expression compared to the
SUM-149 and MDA-MB-436 cell lines.
Immunoprecipitation of AKT1 in the SUM-149 (Figure 3.7A), MDA-MB-436
(Figure 3.7B) and HCC-1937 (Figure 3.7C) cell lines revealed that AKT1 activation
is blocked by inhibition of class I PI3’Kinases (BKM, lane 2), allosteric inhibition of
AKT (MK, lane 3 and 4), inhibition of mTOR (KU, lane 5).

These results

demonstrate that AKT1 phosphorylation is regulated in a manner that is consistent
with canonical PI3’Kinase signaling. Therefore, we can conclude that the class I
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PI3’Kinases are the key regulators of AKT1 activation and that the mTORC2
complex acts as the PDK2 for AKT1. It is also important to note that 1 µM of
MK2206 (lane 3) was sufficient to completely block AKT1 phosphorylation, which
is consistent with knowledge that MK2206 more effectively inhibits the activity of
AKT1 (Yan, 2009).
In contrast to the response of AKT1 phosphorylation, immunoprecipitation
of AKT3 revealed that inhibition of class I PI3’Kinases (BKM, lane 2) or mTOR (KU,
lane 5) failed to completely inhibit AKT3 phosphorylation. This data is most robust
in the SUM-149 cell line (Figure 3.6A) but is also evident in the MDA-MB-436
(Figure 3.6B) and HCC-1937 (Figure 3.6C) cell lines. (Longer exposures of
immunoblots are included in the figure due to the lower levels of AKT3 expression
in these cells compared to the SUM-149 cell line.) Due to a partial reduction of
AKT3 phosphorylation in the presence of BKM (lane2) and KU (lane5), the data
indicate class I PI3’Kinases and mTORC2 contribute to the regulation of AKT3,
however, the marked residual AKT3 phosphorylation in the presence of these
inhibitors suggest that non-canonical PI3’Kinase signaling is contributing to the
activation of AKT3. The residual AKT3 phosphorylation following inhibition of
mTOR (lane 5), indicates that the mTORC2 complex is partially acting as the PDK2
for AKT3 but this data suggests that another kinase is also acting as a PDK2 for
AKT3. Additional work must be done to determine which kinases are contributing
to the phosphorylation of AKT3 at the Ser472 site.
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Immunoprecipitation of AKT3 following treatment with 1 µM and 5 µM
MK2206 (lane 3 and 4, respectively) demonstrated that a higher concentration of
MK2206 was needed to reduce AKT3 phosphorylation (Figure 3.7). This data is
consistent with the knowledge that MK2206 is less effective at inhibiting the activity
of AKT3 (Stottrup et al., 2016); this data further supports our conclusion that AKT
phosphorylation in the SUM-149 and MDA-MB-436 cell line is resistant to MK2206
due to the elevated AKT3 expression in these cells.
By specifically isolating and observing AKT1 and AKT3 phosphorylation in
the SUM-149, MDA-MB-436 and HCC-1937 cell lines (Figure 3.6) we can clearly
see that AKT1 activation is regulated in accordance with canonical PI3’Kinase
signaling while AKT3 activation is not.

Therefore, to determine if AKT3 is

phosphorylated in a PI3’Kinase-dependent manner, we utilized the non-specific
pan class PI3’Kinase inhibitor, wortmannin (Wo, lane 6). As expected, wortmannin
completely inhibited AKT1 phosphorylation, in all three cell lines. Furthermore,
treatment with wortmannin resulted in a total ablation of AKT3 phosphorylation.
This data suggests that AKT3 activation is regulated in a PI3’Kinase dependent
manner, however due to off target effects of wortmannin more specific PI3’Kinase
inhibition is needed to determine which PI3’Kinases are contributing to the
regulation of AKT3.
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Figure 3.6 AKT3 phosphorylation is robust in the presence of
pharmacological inhibition of the PI3’Kinase pathway compared to AKT1
phosphorylation

Figure 3.6 A) SUM-149, B) MDA-MB-436 and C) HCC-1937 cells were grown to 90% confluence
and treated with BKM120 (1 µM), MK2206 (1 µM and 5 µM), Wortmannin (50 nM) or Gefitinib (1
µM) for 2 hr. AKT1 and AKT3 were immunoprecipitated and assessed by Western blot with
Ser472/3/4 and total AKT antibodies, as described in the Methods section. Whole cell lysates
were also probed with Ser472/3/4 and total AKT antibodies for reference. Longer exposures of
immunoblots for MDA-MB-436 and HCC-1937 cells are included to show residual
phosphorylation.
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PI3'Kinase isoform-specific regulation of AKT phosphorylation
Wortmannin is a non-specific pan-class PI3’Kinase inhibitor that is highly
specific for the three classes of PI3’Kinases as well as a family of distantly related
kinases, collectively known as class IV PI3’Kinases (See Table 1 and Figure 3.6A).
To accurately interpret the ability of wortmannin to block AKT3 phosphorylation in
the SUM-149, MDA-MB-436 and HCC-1937 cell lines, we used various isoformspecific PI3’Kinase inhibitors to resolve which kinases are involved in the
regulation of AKT activation.
PI3Kα and PI3Kβ are two of the most commonly studied PI3’Kinase
isoforms (Liu et al., 2009); while the PI3Kα is the most commonly mutated
PI3’Kinase isoform (Bachman et al., 2004), breast cancer studies have identified
the PI3Kβ isoform as the driver of PI3’Kinase signaling in PTEN-null cancers (Wee
et al., 2008). The PI3Kδ and PI3Kγ isoforms are primarily implicated as regulators
of immune cell signaling and diseases of immune cell lineage (Fruman and
Rommel, 2014). These isoforms are rarely expressed in solid tumors and have not
been associated with breast cancer; therefore, inhibitors targeting these molecules
were not included in this dissertation. As discussed previously, wortmannin is a
non-specific pan class PI3'Kinase inhibitor with a high degree of specificity for the
class IV PI3’Kinases; therefore, to ascertain more accurate conclusions about the
regulation of AKT by PI3'Kinases in our cells, we utilized the PI3'Kinase inhibitor
GDC0032. GDC0032, brand named Taselisib, is marketed as a PI3Kβ-sparing
class I PI3'Kinase inhibitor; however, GDC0032 also specifically targets the class
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II PI3'Kinase enzyme, PIK3C2B, and the class III PI3'Kinase (See Table 1) (Lopez
et al., 2014). Based upon these observations, we utilized GDC0032 as a panclass PI3’Kinase inhibitor that would allow us to draw better conclusions about the
regulation of AKT activation that cannot be drawn from experiments utilizing
wortmannin.
Therefore, to determine which PI3’Kinase isoforms are contributing to the
regulation of AKT phosphorylation, we treated the SUM-149, MDA-MB-436 and
HCC-1937 cell lines with 1 µM BKM120 (pan-class I PI3’Kinase inhibitor, internal
control), 1 µM A66 (PI3Kα-specific inhibitor), 1 µM GSK2636771 (PI3Kβ-specific
inhibitor), 1 µM SAR405 (class III PI3’Kinase-specific inhibitor) or 1 µM GDC0032
(pan-class PI3’Kinase inhibitor) for 2 hr and assessed for total AKT
phosphorylation by western blot. The failure of A66 to reduce AKT phosphorylation
(Figure 3.7) in the three cell lines tested suggests that PI3Kα is not a potent
regulator of AKT activation in this setting. This result is consistent with the notion
that PI3Kα is a driver in PIK3CA mutant cancers and not PTEN-null cancers (Juric
et al., 2015; Schwartz et al., 2015; Wee et al., 2008). We hypothesized that
inhibition of PI3Kβ would reduce AKT phosphorylation in the three cell lines due to
the literature that suggest that PI3’Kinase signaling in PTEN-null cancers is
dependent upon the PI3Kβ isoform. Interestingly, GSK2636771 failed to reduce
AKT phosphorylation in the SUM-149 cell line (Figure 3.7A, lane 4); however, GSK
did result in a marginal reduction of AKT phosphorylation in the MDA-MB-436 cell
line (Figure 3.7B, lane 4) and had the greatest effect in the HCC-1937 cell line
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(Figure 3.7C, lane 4). This data suggests that the PI3Kβ isoform operates as driver
of PI3’Kinase signaling in some PTEN-null breast cancers also indicate that the
loss of PTEN is not consistently the determinant factor by which cells become
dependent upon the PI3Kβ isoform as a driver of PI3’Kinase signaling. This data
is clinically significant because it highlights the importance of personalized
treatment strategies for breast cancer patients; cell lines are isolated from patient
tumors and just as each cell is unique in its molecular profile so are the patient
tumors from which they were derived. Therefore, broadly categorizing patient
samples, and consequentially cancer cell lines, on the manifestation of general
molecular events will not be beneficial to the patients whose disease does not
respond in the conventional manner.
As expected, inhibition of class III Pi3’Kinase enzymatic activity, by SAR,
had no effect on AKT phosphorylation in any of the cell lines tested. Class III
PI3’Kinases produce PtdIns(3)P and primarily function in the processes of
autophagy and membrane trafficking (Ronan et al., 2014) Based upon the cell’s
ability to used other PtdIns species as precursors for the formation of PtdIns(3,4)P2
and PtdIns(3,4,5)P3 (see Figure 1.6) and because class III PI3’Kinases are not
implicated in breast cancer, it was not surprising that SAR did not inhibit AKT
phosphorylation in the cell lines tested (Figure 3.7, lane 5).
GDC0032 inhibits all class I PI3’Kinases, the class II PI3K-C2β isoform and
the class III PI3’Kinase; treatment of the MDA-MB-436 (Figure 3.7B, lane 6) and
HCC-1937 (Figure 3.7C, lane 6) cell lines with 1 µM of GDC0032 was able to
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completely block AKT phosphorylation in these cell lines. The reduction of AKT
phosphorylation in the SUM-149 cell line following treatment with 1 µM GDC did
not elicit the same reduction of AKT phosphorylation as seen in the MDA-MB-436
and HCC-1937 cell lines. However, because GDC0032 was capable of inhibiting
AKT3 phosphorylation in the MDA-MB-436 cell line, which expresses half the
amount of AKT3 than the SUM-149 cell line, we hypothesized that the elevated
expression of AKT3 in the SUM-149 cell line is contributing to the resistance of
AKT phosphorylation to inhibition of GDC.
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Name of inhibitor, type of inhibitor, mechanism of action and concentration of drug that results in 50% inhibition (IC50) of specific
molecular targets. EGFR-epidermal growth factor receptor; TKI- tyrosine kinase inhibitor, PI3Kα- p110α (PIK3CA) catalytic
enzyme; PI3Kβ- p110β (PIK3CB) catalytic enzyme; PI3Kδ- p110δ (PIK3CD) catalytic enzyme; PI3Kγ- p110γ (PIK3CG) catalytic
enzyme; C2B- PI3K-C2β (PIK3C2B) catalytic enzyme; Vps34- Class III PI3’Kinase; mTOR- mammalian target of rapamycin;
PLK1- polo-like kinase 1; PI4KB-phosphatidylinositol 4-Kinase β isoform; DNA-PK DNA dependent-protein kinase; ATM- ataxia
telangiectasia mutated; MLCK- myosin light chain kinase; AKT- protein kinase B. IC50 concentrations greater than 1 µM are
considered non-specific Figure 3.6A illustrates simplified schematic of PI3K/AKT signaling network and the inhibitors used in
this study/

Table 1: Pharmacological inhibitors used in Dissertation

Figure 3.6A Schematic of canonical and non-canonical PI3’Kinase/AKT
signaling cascade depicting sites of action by inhibitors

Figure 3.6 A simplified schematic of canonical and non-canonical PI3’Kinase/AKT signaling and
therapeutic targets. Black arrows denote PH domain binding of kinases to phosphatidylinositol
species. Blue arrows denote activating connections. Red lines denote inhibitory effect of the
pharmacological inhibitors used in this study.
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Figure 3.7 Specific inhibition of PI3'Kinase enzymes reveals that pan-Class
PI3'Kinase inhibition has the greatest effect on AKT phosphorylation in
basal-like triple negative breast cancer cell lines

Figure 3.7 A) SUM-149, B) MDA-MB-436 and C) HCC-1937 cells were treated at 1 µM for 2 hr
with BKM120 (pan Class I PI3’Kinase inhibitor), A66 (Class I PI3’Kinase α inhibitor), GSK2636
(Class I PI3’Kinase β inhibitor), SAR405 (Class III PI3’Kinase inhibitor) and GDC0032 (pan-Class
PI3’Kinase inhibitor). AKT phosphorylation was assessed by western blot.
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Elevated AKT3 protein expression results in resistance of cells to pan-class
PI3’Kinase inhibition by GDC0032
GCD0032 is marketed as a PI3Kβ sparing PI3’Kinase inhibitor; however, it
inhibits all classes of PI3’Kinases in the nanomolar range. It inhibits PI3Kα, PI3Kβ,
PI3Kδ, PI3Kγ, PI3K-C2β, and Vsp34 at 0.29 nM, 9.1 nM, 0.12 nM, 0.97 nM, 292
nM and 374 nM, respectively (See Table 1). Our data indicate that class II
PI3’Kinases, specifically PI3K-C2β, is a major driver of PI3’Kinase-mediated
signaling in cell lines with elevated AKT3 protein expression. GDC0032 has a 32fold higher inhibitory concentration for PI3K-C2β than the class I PI3’Kinase
isoforms, we hypothesized that higher concentrations of GDC0032 will be needed
to effectively inhibit PI3K-C2β activity and subsequent AKT phosphorylation,
specifically AKT3 phosphorylation, in the SUM-149 cell line.
To determine if higher concentrations of GDC0032 is needed to reduce AKT
phosphorylation in the SUM-149 cell line, we treated the SUM-149, MDA-MB-436
and HCC-1937 cell lines with 1 µM, 3 µM and 5 µM GDC0032 for 2 hr and
assessed AKT phosphorylation by western blot (Figure 3.8A). As seen in Figure
3.7A, 1 µM of GDC was insufficient to reduce AKT phosphorylation in the SUM149 cell line, but the data in Figure 3.8 revealed that higher concentrations of GDC
were able to block AKT phosphorylation in the SUM-149 cell line. Therefore, we
hypothesized that AKT3 phosphorylation was more resistant to GDC than AKT1
phosphorylation. To test our hypothesis, we treated the SUM-149 cells with 1 µM
and 3 µM GDC0032 for 2 hrs and then immunoprecipitated AKT1 and AKT3 from
the lysates and immunoblotted for phosphorylated AKT. The data in Figure 3.8B
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reveals that AKT1 phosphorylation is completely inhibited by 1 µM of GDC0032; in
contrast, AKT3 phosphorylation persisted in the presence of 1 µM GDC0032 and
was nearly inhibited by 3 µM of GDC. We conclude that the elevated expression
of AKT3 in the SUM-149 cell line confers the resistance of AKT phosphorylation in
these cells to GDC.
To confirm our results and to test the hypothesis that elevated AKT3 expression in
PTEN-null cell lines results non-canonical PI3’Kinase signaling and require panclass PI3’Kinase inhibition to effectively block AKT phosphorylation, we treated the
AKT3-null HCC-38 cell line with 1 µM BKM120, 1 µM A66, 1 µM GSK2636, 1 µM
GDC0032, and 500 nM wortmannin for 2 hr and assessed total AKT
phosphorylation by western blot (Figure 3.9). Our results indicate that PI3Kα and
PI3Kβ, independently are not drivers of PI3’Kinase signaling in these cells but that
class I PI3’Kinase inhibition is required to dramatically effect AKT phosphorylation.
Our results also indicate that 1 µM of GDC sufficiently reduces AKT
phosphorylation and supports our hypothesis that higher expression of AKT3
requires more concentrated inhibition of PI3K-C2β to block non-canonical
PI3’Kinase signaling.
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Figure 3.8 GDC0032, a pan-class PI3’Kinase inhibitor, requires higher
concentrations of drug to reduce AKT3 phosphorylation in the SUM-149
cell line

Figure 3.8 A) SUM-149, MDA-MB-436, and HCC-1937 cell lines were treated with GDC0032
(1 µM, 3 µM, or 5 µM) for 2 hr. AKT phosphorylation was assessed by western blot. B) SUM149 cells were treated with GDC0032 (1 µM and 3 µM) for 2 hr and lysates were
immunoprecipitated with antibodies specific for AKT1 and AKT3. Immunoprecipitated lysates
and whole cell lysate were immunoblotted for phospho-AKT. The bar graph shows the
results of densitometry analysis of phospho-AKT inhibition in treated cells normalized to the
control sample.
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Figure 3.9 The PTEN-null, AKT3-null HCC-38 cell line requires pan-Class
I inhibition to effectively reduce AKT phosphorylation

Figure 3.9 HCC-38 cells were treated with BKM120 (1 µM), A66 (1 µM), GSK2626 (1 µM),
GDC0032 (1 µM) and Wortmannin (500 µM). Bar graph represents densitometry of phospho-AKT
of each treatment group normalized to phospho-AKT in the control sample.
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Cooperative effect of PI3Kα and PI3Kβ inhibition on AKT is contextdependent
The literature suggests that PI3Kβ is the predominant PI3’Kinase isoform
driving PI3’Kinase-depenedent signaling in PTEN-null cancers (Wee et al., 2008).
Furthermore, the literature also suggests that dual inhibition of PI3Kβ and
PI3Kα can synergize to reduce PI3’Kinase signaling more efficiently than inhibition
of PI3Kβ alone (Hosford et al., 2017; Wee et al., 2008). Our data has suggested
that inhibition of PI3Kβ alone has variable effects on AKT phosphorylation in the
PTEN-null cell lines tested (Figure 3.7). We hypothesized than a greater reduction
of AKT phosphorylation will occur upon dual inhibition of PI3Kβ and
PI3Kα compared to the reduction observed by inhibition of PI3Kβ alone.
To test this hypothesis, we treated the SUM-149 (Figure 3.10), SUM-185
(Figure 3.11), MDA-MB-436 (Figure 3.12) and HCC-1937 cell line (Figure 3.13)
with a PI3Kα-specific inhibitor (A66), a PI3Kβ-specific inhibitor (GSK2636) or a
combination of A66 and GSK2636 for 2 hr and assessed AKT phosphorylation by
western blot.
Our results indicate that dual inhibition of PI3Kα and PI3Kβ co-operates to
reduce AKT phosphorylation in the SUM-149 cell line greater than inhibition of
PI3Kβ alone (Figure 3.10, lane 5 vs lane 4), but reveals that pan-class PI3’Kinase
inhibition is required to dramatically reduce AKT phosphorylation in these cells
(lane 7). From this data we can conclude that class I PI3Kα and PI3Kβ isoforms
are contributing to the regulation of AKT activation in the SUM-149 cell line,
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however, inhibition of PI3K-C2β is required to inhibit the non-canonical PI3’Kinase
signaling that regulating AKT activation in these cells.
The PTEN WT, PIK3CA mutant SUM-185 cell line, was included as a
control to determine the response of AKT phosphorylation in a cell line in which
the PI3Kα isoform is the predominant driver of signaling. As expected, inhibition
of PI3Kα (Figure 3.11, lane 2) alone was sufficient to reduce AKT phosphorylation
in these cells at a level comparable to dual PI3Kα and PI3Kβ inhibition (lane 4) and
class I PI3’Kinase (lane 5) inhibition. From this data, we conclude that PIK3CA
mutant cell lines are dependent upon PI3Kα for signal transduction and the data
indicate that cells driven by a specific PI3’Kianse isoform benefit from specific
inhibition of the driving isoform.
Dual inhibition of PI3Kα and PI3Kβ in the MDA-MB-436 cell line (Figure
3.12, lane 4) did not result in a greater inhibition of AKT phosphorylation than
inhibition of PI3Kβ alone (lane 3), suggesting that PI3Kβ is the predominant driver
of class I PI3’Kinase mediated signaling in the MDA-MB-436 cell line.

We

conclude that inhibition of both class I and class II PI3’Kinase enzymes is required
to block AKT phosphorylation in these cells (lane 6), further supporting our
conclusion that class II PI3’Kinases and specifically, PI3K-C2β is regulating the
non-canonical signaling pathway that is active in these cells.
As shown before, sole inhibition of PI3Kβ in the HCC-1937 cell line (Figure
3.13), results in a dramatic reduction of AKT phosphorylation and highlights the
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importance of PI3Kβ in these cells (lane 3).

Dual inhibition of PI3Kα and

PI3Kβ (lane 4) resulted in a greater reduction of AKT phosphorylation than
inhibition of PI3Kβ alone, yet no further reduction of AKT phosphorylation was
observed upon inhibition of class I PI3’Kinases (lane 5).
Taken together, the data indicate that AKT phosphorylation in PTEN-null basal
breast cancer cell lines with elevated AKT3 expression are regulated by canonical
and non-canonical PI3’Kinase activity. We conclude that PI3Kβ functions as the
predominant driver of canonical signaling in PTEN-null basal breast cancer cell
lines (this is context dependent), however inhibition of canonical PI3’Kinase
enzymes is not sufficient to effectively inhibit AKT phosphorylation in these cells.
Inhibition of PI3K-C2β in conjunction with inhibition of class I PI3’Kinases is
required to inhibit the non-canonical signaling axis leading to AKT activation in
these cells.
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Figure 3.10 AKT phosphorylation in the SUM-149 cell line is driven by
PI3Kα and PI3Kβ but multiple classes of PI3’Kinase cooperate to regulate
AKT activation

Figure 3.10 SUM-149 cells were treated with PI3Kα inhibitor, A66 (1 µM and 3 µM),
PI3Kβ inhibitor, GSK2636 (1 µM), a combination of A66 (1 µM or 3 µM) and GSK2636 (1 µM), or
GDC0032 (3 µM) for 2 hr. AKT-phosphorylation was assessed by western blot. The bar graph
shows quantitative analysis of AKT phosphorylation for each treatment group normalized to control
SUM-149 cells.
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Figure 3.11 PI3Kα is the driver PI3’Kinase in the PIK3CA mutant SUM-185
cell line

Figure 3.11 SUM-185 cells were treated with PI3Kα inhibitor, A66 (1 µM), PI3Kβ inhibitor,
GSK2636 (1 µM), a combination of A66 (1 µM) and GSK2636 (1 µM), Class I PI3’Kinase inhibitor,
BKM120 (1 µM), or GDC0032 (3 µM) for 2 hr. AKT-phosphorylation was assessed by western
blot. The bar graph shows quantitative analysis of AKT phosphorylation for each treatment group
normalized to control SUM-185 cells.
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Figure 3.12 AKT phosphorylation in the MDA-MB-436 cell line is
cooperatively regulated three classes of PI3’Kinase

Figure 3.12 MDA-MB-436 cells were treated with PI3Kα inhibitor, A66 (1 µM), PI3Kβ inhibitor,
GSK2636 (1 µM), a combination of A66 (1 µM) and GSK2636 (1 µM), Class I PI3’Kinase inhibitor,
BKM120 (1 µM), GDC0032 (3 µM), or Wortmannin (500 nM) for 2 hr. AKT-phosphorylation was
assessed by western blot. The bar graph shows quantitative analysis of AKT phosphorylation for
each treatment group normalized to control MDA-MB-436 cells.
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Figure 3.13 AKT phosphorylation in the HCC-1937 cell line is driven by
PI3Kα and PI3Kβ isoforms

Figure 3.13 HCC-1937 cells were treated with PI3Kα inhibitor, A66 (1 µM), PI3Kβ inhibitor,
GSK2636 (1 µM), a combination of A66 (1 µM) and GSK2636 (1 µM), Class I PI3’Kinase inhibitor,
BKM120 (1 µM), GDC0032 (3 µM), or Wortmannin (500 nM) for 2 hr. AKT-phosphorylation was
assessed by western blot. The bar graph shows quantitative analysis of AKT phosphorylation for
each treatment group normalized to control HCC-1937 cells.
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Differential response of AKT1 and AKT3 phosphorylation to isoform-specific
PI3'Kinase inhibitors
Our data indicate that AKT1 phosphorylation is regulated by canonical class
I PI3’Kinase signaling while AKT3 activation is regulated by non-canonical
PI3’Kinase signaling, particularly the class II PI3K-C2β isoform. Our data also
suggest that the PI3Kβ contributes to class I PI3’Kinase enzymatic activity in some
PTEN-null basal breast cancer cell lines and can be considered a driver of class I
PI3’Kinase regulation in a subset of cell lines (Figure 12 and Figure 13). Our data
also indicate that dual inhibition of PI3Kα and PI3Kβ co-operate to regulate AKT
activation in other PTEN-null cell lines (Figure 10 and Figure 13). Based upon this
data we hypothesize that AKT1 specific activation is more sensitive to inhibition of
class I PI3’Kinase isoforms and that AKT3 activation may be regulated in part by
class I PI3’Kinase isoforms but complete AKT3 inhibition will only occur in the
presence of pan-class I PI3’Kinase and C2β inhibition (GDC0032). To test this
hypothesis we treated the SUM-149 (Figure 3.14), MDA-MB-436 (Figure 3.15) and
HCC-1937 (Figure 3.16) cell lines with 1 µM BKM120, 1 µM A66, 1 µM GSK2636,
3 µM GDC0032, and 500 nM wortmannin for 2 hr. Cell lysates were harvested
and AKT1 and AKT3 were immunoprecipitated and assessed by western blot.
As demonstrated previously, pan-class I PI3’Kinase inhibition is capable of
inhibiting

AKT1

phosphorylation

but

only

marginally

reduces

AKT3

phosphorylation in all three cell lines (Figure 14,15 & 16, lane 2). As expected,
inhibition of PI3Kα (A66) failed to inhibit AKT1 or AKT3 specific phosphorylation
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(lane 3), therefore, we conclude that PI3Kα does not drive class I PI3’Kinase
mediated AKT activation in cell lines in cell lines without a PIK3CA mutation.
Inhibition of PI3Kβ (GSK) partially inhibited the activation of AKT1 in the MDA-MB436 (Figure 3.15, lane4) and HCC-1937 (Figure 3.16, lane 4), confirming our
hypothesis and demonstrating that PI3Kβ is a driver of AKT1 activation in these
cells. Taken together we conclude that AKT1 activation is regulated by canonical
PI3’Kinase signaling, that pan-class I PI3’Kinase inhibition is sufficient to inhibit
AKT1 phosphorylation and that class I PI3’Kinases cooperate to regulate AKT1
activation. The mechanism governing the context in which specific PI3’Kinase
isoforms function to produce specific PtdIns species and the context in which
PI3Kβ functions as the major driver of class I PI3’Kinase signaling is still unknown.
The response of AKT3 phosphorylation to the specific inhibition of PI3Kβ
(GSK2636771) in the SUM-149 cell line was unique in that AKT3 phosphorylation
was slightly elevated in the presence of PI3Kβ inhibition.

A recent study,

examining the mechanisms of PI3Kβ signaling in PTEN-mutated cancers
demonstrated that PI3Kα is not a driver of signaling in PTEN mutated cancers
(Wee et al., 2008). However, inhibition of the PI3Kβ isoform alone in the SUM-149
cell line resulted in rebound AKT activation that was driven by PI3Kα (Schwartz et
al. 2015). These data, in conjunction with the data presented in this dissertation,
suggest that the mechanism governing the isoform-specific regulation of AKT
activation is complex and multifaceted; however, the data presented in our study
clearly demonstrate that inhibition pan-class I and C2β is sufficient to inhibit AKT1
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and AKT3 activation in each cell line tested. Although AKT3 phosphorylation in the
MDA-MB-436 (Figure 3.15) and HCC-1937 (Figure 3.16) cell lines was slightly
decreased in response to PI3Kβ inhibition (GSK2636771), ablation of AKT3
phosphorylation only occurred in the presence of pan-class PI3’Kinase inhibition
(GDC0032). Taken together these results
Although AKT3 phosphorylation in the MDA-MB-436 (Figure 3.15) and
HCC-1937 (Figure 3.16) cell lines was slightly decreased in response to PI3Kβ
inhibition (GSK2636771), ablation of AKT3 phosphorylation only occurred in the
presence of pan-class PI3’Kinase inhibition (GDC0032). Taken together indicate
that class I and class II PI3’Kinase family members play an important role in the
activation of AKT3 in PTEN-null basal breast cancer cell lines.
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Figure 3.14 Differential response of AKT1 and AKT3 in the SUM-149 cell line
to isoform-specific PI3’Kinase pathway inhibitors

Figure 3.14 SUM-149 cells were treated with BKM120 (1 µM), A66 (1 µM), GSK2636 (1 µM),
GDC0032 (3 µM) and Wortmannin (500 nM) for 2 hr and lysates were immunoprecipitated with
antibodies specific for AKT1 and AKT3. Immunoprecipitated lysates and whole cell lysate were
immunoblotted for phosphorylated AKT. The bar graph displays the results of quantitative
analysis of phospho-AKT inhibition in treated cells normalized to the control sample.
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Figure 3.15 Differential response of AKT1 and AKT3 in the MDA-MB-436 cell
line to isoform-specific PI3'Kinase pathway inhibitors

Figure 3.15 MDA-MB-436 cells were treated with BKM120 (1 µM), A66 (1 µM), GSK2636 (1 µM),
GDC0032 (3 µM) and Wortmannin (500nM) for 2 hr and lysates were immunoprecipitated with
antibodies specific for AKT1 and AKT3. Immunoprecipitated lysates and whole cell lysate were
immunoblotted for phospho-AKT. The bar graph displays the results of quantitative analysis of
phospho-AKT inhibition in treated cells normalized to the control sample.
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Figure 3.16 Differential response of AKT1 and AKT3 in the HCC-1937 cell
line to isoform-specific PI3'Kinase pathway inhibitors

Figure 3.16 HCC-1937 cells were treated with BKM120 (1 µM), A66 (1 µM), GSK2636 (1 µM),
GDC0032 (3 µM) and Wortmannin (500nM) for 2 hr and lysates were immunoprecipitated with
antibodies specific for AKT1 and AKT3. Immunoprecipitated lysates and whole cell lysate were
immunoblotted for phospho-AKT. The bar graph displays the results of quantitative analysis of
phospho-AKT inhibition in treated cells normalized to the control sample.
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Pan class PI3’Kinase inhibition by GDC0032 reduces clonogenicity in the
SUM-149 cell line
To determine the functional significance of inhibiting AKT3 activity, we
performed a colony forming assay to determine if inhibition of pan-class PI3’Kinase
enzymes would result in a reduction of clonogenicity. To test this, we measured
the colony forming efficiency (CFE) of the SUM-149 cells treated with 3 µM
GDC0032. For these experiments, we also treated the SUM-149 cells with 1 µM
Gefitinib and a combination of Gefitinib and GDC0032 to determine if inhibition of
AKT3 phosphorylation coupled with EGFR inhibition would increase the efficacy of
EGFR inhibition in these cells. The data in Figure 3.17 shows that EGFR inhibition
alone does not reduce the clonogenic potential of SUM-149 cells. Interestingly,
treatment with GDC0032 alone resulted in an approximately 5-fold decrease in the
clonogenic potential of SUM-149 cells, suggesting that inhibition of AKT3 activity
due to the inhibition of class I PI3’Kinases and PI3K-C2β is sufficient to reduce
clonogenicity. Strikingly, GDC0032 treatment in combination with EGFR inhibition
resulted in an approximately 17-fold reduction in the clonogenic potential of SUM149 cells,. We can data strongly suggest that the subset of basal breast cancer
patients with elevated EGFR and elevated AKT3 expression that inhibition of class
I PI3’Kinases and PI3K-C2b in conjunction with inhibition of EGFR may serve as
a new treatment strategy for patients presenting with this disease.
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Figure 3.17 Pan Class PI3’Kinase inhibition dramatically reduces the
clonogenic potential of SUM-149 cells and combined pan class PI3’Kinase
and EGFR inhibition results in a further reduction in clonogenicity
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Figure 3.17 SUM-149 cells were seeded (1x103) per well after overnight attachment cells were
treated with Gefitinib (1 µM), GDC0032 (3 µM) or a combination of Gefitinib (1 µM) and GDC0032
(3 µM) for 72hrs. Cells were fixed and stained once colonies contained approximately 50 cells.
Bars represent colony forming efficiency, as described in the methods section. Error bars
represent the range of the data of three replicates.
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Re-expression of PTEN in a subset of basal-like breast cancer cell lines
ineffectively inhibits AKT activity
The data presented in this study has identified a non-canonical PI3’Kinase
signaling mechanism that regulates the activation of AKT3 through class I
PI3’Kinases but also the class II PI3’Kinase isoform, PI3K-C2β in a subset of
PTEN-null basal breast cancer cell lines. We concluded that the SUM-149 and
MDA-MB-436 cell line displayed resistant AKT phosphorylation to inhibition
PI3’Kinase pathway mediators and this was contributed to the elevated of AKT3
expression in these two cell lines. We now understand the contribution of elevated
AKT3 expression to the PI3’Kinase signaling landscape in the SUM-149 and MDAMB-436 cell line, therefore, we wanted to determine how PTEN loss affects the
signaling landscape present in basal breast cancer cell lines. To examine this, we
restored PTEN expression in the panel of basal-like breast cancer cell lines. We
hypothesize, based on the data presented in this study, that PTEN re-expression
will reverse the constitutive AKT activation in cells lines with low level AKT3
expression.
To re-express PTEN in the panel of PTEN-null basal-like breast cancer cell
lines, pLenti6.3/PTEN ORF Gateway expression vectors were generated using the
Gateway Cloning System as described in the Materials and Methods chapter.
HCC-38, SUM-149, MDA-MB-436, MDA-MB-468 and HCC-1937 cell lines were
stably infected with the PTEN ORF lentiviral expression constructs, and PTEN
protein expression and the effect of PTEN re-expression on the AKT
phosphorylation were assessed by western blot (Figure 3.18). As expected, re114

expression of PTEN resulted in variable effects on AKT phosphorylation in the
panel of basal-like breast cancer cells. A robust reduction of AKT phosphorylation
was observed in the MDA-MB-468 and HCC-1937 cell lines, while minimally
reducing AKT phosphorylation in the HCC-38, SUM-149 and MDA-MB-436 cell
lines (Figure 3.19). The failure of PTEN re-expression to reverse the constitutive
AKT activation in the SUM-149 and MDA-MB-436 cell line was expected due to
the resistance of AKT3 phosphorylation to inhibitors of canonical PI3’Kinase
activity. However, the residual AKT phosphorylation in the PTEN re-expressing
HCC-38 cell lines was unexpected since this is an AKT3-null cell line. This
suggests that in the context of loss of AKT3 expression that AKT2 may be
compensating for the loss of AKT3 and its activity is regulated in by non-canonical
PI3’Kinase signaling. To determine if AKT2 compensates for loss of AKT3 in the
HCC-38 cell line, future studies assessing AKT2 specific phosphorylation in the
presence of PTEN re-expression and inhibitors of the PI3’Kinase signaling
cascade would give insight into the activation of AKT signaling in an AKT3-null
setting.
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Figure 3.18 PTEN re-expression has differential effects on AKT
phosphorylation in basal-like triple negative breast cancer cell lines

Figure 3.18 HCC-38, SUM-149, MDA-436, MDA-MB-468 and HCC-1937 cells were
stably infected with GFP and PTEN ORF lentiviral expression constructs. PTEN protein
expression was confirmed in the PTEN-null basal breast cancer cell line panel by western
blot. The effect of PTEN expression on AKT phosphorylation was assessed by western
blot. PTEN re-expression had the greatest effect on AKT phosphorylation in the MDAMB-436 and HCC-1937 cell lines.
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Re-expression of PTEN results in the restoration of canonical PI3’Kinase
pathway signaling in basal breast cancer cell lines
Our data demonstrate that AKT activation in PTEN-null basal breast cancer
cell lines is regulated by canonical and non-canonical PI3’Kinase signaling.
Therefore, this led us to examine the role that PTEN loss plays in the non-canonical
PI3’Kinase signaling present in our PTEN-null basal breast cancer cell line panel.
To answer this question, PTEN re-expressing versions of SUM-149 (Figure 3.19A)
and MDA-MB-436 (Figure 3.19B) cell lines were treated with 1 uM BKM120 (panclass I PI3’Kinase inhibitor), 1 uM MK2206 (allosteric AKT inhibitor) or 1 uM
KU0063794 (pan mTOR inhibitor) for 2 hr and assessed for total AKT
phosphorylation by western blot. Re-expression of PTEN in the SUM-149 cell line
resulted in the reduction of AKT phosphorylation in response to pan class I
PI3’Kinase inhibition, allosteric AKT inhibition and mTOR inhibition. The data
indicate that in PTEN-re-expressing cells, inhibition of class I PI3’Kinases is now
sufficient to inhibit AKT phosphorylation in the SUM-149 cell line (Figure 3.19A),
suggesting that even though PTEN re-expression failed to reduce AKT
phosphorylation, that PTEN must be interacting with the non-canonical PI3’Kinase
signaling cascade. This result is important because the data presented in this
study has shown that inhibition of class I PI3’Kinases is not capable of substantially
inhibiting AKT phosphorylation in the SUM-149 cell line due to the presence of a
non-canonical PI3’Kinase signaling cascade that governs the activation of AKT3
and subsequently global AKT phosphorylation in these cells. Therefore, the ability
of class I PI3’Kinase inhibition in the presence of PTEN re-expression in the SUM117

149 cell line to now inhibit AKT phosphorylation indicates that restoration of PTEN
results in the restoration of the canonical PI3’Kinase signaling cascade. The data
in Figure 3.19A also reveals that inhibition of mTOR in the SUM-149 PTEN reexpressing cells is now able to substantially reduce AKT phosphorylation
compared to the control cells and suggests that the mTORC2 complex is now the
predominant PDK2 in the SUM-149 cell line.

Based upon these results, we

hypothesize that PTEN re-expression would result in a reduction of AKT3
phosphorylation and that inhibition of mTOR, in this context, would result in greater
reduction of AKT3 specific phosphorylation than seen in the control cells. Further
investigation is needed to understand how PTEN re-expression affects AKT
isoform-specific activation in PTEN-null basal breast cancer cell lines.
The data in Figure 3.19B show the response of AKT phosphorylation in the
MDA-MB-436 cell line in the presence of PTEN re-expression. While the results
of this experiment are not as dramatic as the results seen in the SUM-149 cell line,
the data suggest that the canonical PI3’Kinase signaling cascade is now more
active in PTEN re-expressing MDA-MB-436 cells compared to control MDA-MB436 cells. This is evidenced by the enhanced reduction of AKT phosphorylation in
the presence of class I PI3’Kinase, allosteric AKT and mTOR inhibition in the PTEN
re-expressing MDA-MB-436 cell line compared to control.
Taken together, the data presented in this dissertation reveal that basal
breast cancers that have lost PTEN and have AKT3 expression are regulated by
canonical and non-canonical PI3’Kinase signaling. In these cells, AKT1 activation
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is regulated by the canonical PI3’Kinase cascade, while AKT3 is regulated in part
by canonical PI3’Kinase signaling but is also governed by a non-canonical
PI3’Kinase cascade in which the class II PI3’Kinase, PI3K-C2β, contributes to the
activation of AKT3.

Our data demonstrate that the restoration of canonical

PI3’Kianase signaling as primary regulator of AKT activation can be achieved
through restoration of PTEN expression. These results provide a rational basis for
targeting class I and class II PI3’Kinase enzymes for the effective inhibition of
PI3’Kinase signaling in PTEN-null basal breast cancer cell lines.
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Figure 3.19 PTEN re-expression in SUM-149 and MDA-MB-436 cell lines
leads to restoration of canonical PI3'Kinase signaling

Figure 3.19 A) SUM-149 and B) MDA-436 cells stably infected with GFP or PTEN
ORF lentiviral expression constructs were treated with 1 µM BKM120, 1 µM
MK2206, or 1 µM KU0063794. The effect of PTEN expression on AKT
phosphorylation in the presence of canonical PI3’Kinase pathway mediators was
assessed by western blot. PTEN re-expression resulted in restoration of the
canonical PI3'Kinase signaling cascade.
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Chapter 4:
Discussion
Basal-like breast cancer is one of the five molecular subtypes of breast
cancer and affects 15-20% of cancer patients. Patients presenting with basal-like
breast cancer often present with high-grade tumors and tend to have a poorer
prognosis compared to the other subtypes (Sorlie et al., 2001). Due to a lack of
molecular targets, cytotoxic neoadjuvant chemotherapy is the standard of
treatment for patients presenting with basal-like breast cancer (Bertucci et al.,
2012). Despite a large portion of patients exhibiting a favorable response to
neoadjuvant chemotherapy, a disproportionate number of patients fail to achieve
a pathologic complete response (pCR) and ultimately die due to metastatic
disease. This population of patients that fail to achieve a pCR is indicative of the
intrinsic resistance of this subtype to chemotherapy (Badve et al., 2011; Bertucci
et al., 2012; Da Silva et al., 2007; Lehmann et al., 2011).
A subset of basal-like breast cancers are characterized by the loss of PTEN
expression, the presence of p53 inactivating mutations and over-expression of
EGFR (Pires et al., 2013). Pires et al. demonstrated that altering MCF-10A cells
by introduction of a p53 inactivating mutation, deletion of PTEN expression and
EGFR-overexpression

was

able

to

recapitulate

common

phenotypic

characteristics observed in the basal-like breast cancers, such as increased
proliferation and elevated AKT activation. Taken together, mutant p53, loss of
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PTEN expression and over-expression of EGFR cooperate in a subset of basal
breast cancers, which regulate the aggressive nature of the basal-like subtype.
This dissertation was designed to investigate the signaling landscape present
within PTEN-null basal-like breast cancer cell lines with the goal of identifying
potential therapeutic strategies that would effectively block the constitutively
activated PI3’Kinase/AKT signaling pathway.
Preclinical studies involving BKM120 (buparlisib) indicated that pan-class I
PI3’Kinase inhibition was more effective in cell lines harboring PIK3CA mutations
and in TNBC cancers with BRCA1/2 mutations (Estevez et al., 2016). Thus this
led to the hypothesis that treatment with BKM120 in conjunction with PARP
inhibitors would be a potential treatment strategy for breast cancer patients
(Estevez et al., 2016; Matulonis et al., 2017).

However, despite promising

preclinical data, clinical trials investigating the efficacy of BKM120 for the treatment
of breast cancer however, early phase clinical trials have identified a high-toxicity
profile for BKM120 in patients and a lack of tumor response (Martin et al., 2017).
Currently, clinical trials measure the efficacy of drugs in patient populations based
upon the treatment of patients with the MTD. Therefore, because patients are
treated with excessive amounts of drug rather than with the MED, adverse events
typically outweigh any clinical benefit that could be potentially garnered from the
treatment strategy. The dose-limiting toxic events associated with BKM120 are
likely due to the large number of cellular processes that involve class I PI3'Kinases,
as well as the lack of patient stratification within the selection criterion.
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Unfortunately, clinical trials involving BKM120 have not prospectively stratified
patients based on PI3'Kinase pathway activating events, such as PIK3CA
mutations.

Retrospective analyses of patients treated with BKM120 failed to

identify a clinical response in patients with metastatic breast cancer due to patients
not being good candidates for treatment (Martin et al., 2017; Zhao et al., 2017).
PI3’Kinase signaling has been implicated as an important factor in the
progression of breast cancer (Lopez-Knowles et al., 2010; Moulder, 2010; Saal et
al., 2007; Zhao and Vogt, 2008). The failure of BKM120 to produce a favorable
response in phase II clinical trials and the failure of BKM120 to progress past phase
III clinical trials suggests that our understanding of the PI3’Kinase pathway is
incomplete and indicates that further investigation is needed to understand this
pathway and the identification of predictive biomarkers for sensitivity to BKM120 is
needed.
In support of this, we found that BKM120 failed to completely inhibit AKT
phosphorylation in most of the cell lines tested in the cell line panel, and this data
suggests that AKT activation is not completely driven by class I PI3’Kinase activity
(canonical PI3’Kinase signaling) (Figure 1).
Preclinical studies utilizing KU0063794 have shown that pan-inhibition of
mTOR molecules is capable of inhibiting AKT phosphorylation at the Ser473 site,
suggesting that the mTORC2 complex acts as the PDK2 for AKT. However, a
study published by Lee et al. revealed that in MDA-MB-468 cells, the mTORC2
complex was not the only PDK2 involved in the activation of AKT; this study
123

suggested that integrin-linked kinase (ILK) was responsible for phosphorylating
AKT at the Ser473 site in these cells (Lee et al., 2013). In agreement with this
study, we also saw incomplete inhibition of AKT phosphorylation following panmTOR inhibition in MDA-MB-468 cells (Figure 1).
In our studies, immunoprecipitation of AKT1 and AKT3 in the SUM-149,
MDA-MB-436 and HCC-1937 cell lines revealed that AKT1 phosphorylation is
inhibited following mTOR inhibition with KU006397, while AKT3 specific
phosphorylation persisted in the presence of pan-mTOR inhibition in all three cell
lines. This suggests that mTORC2 is not the sole kinase phosphorylating AKT3 at
the Ser472 site, at least in these cells. Further work is needed to determine which
kinase(s) may be functioning as the PDK2 for AKT3 in PTEN-null basal breast
cancer cell lines.
Our results also revealed that the allosteric AKT inhibitor, MK2206, failed to
completely inhibit AKT phosphorylation in the SUM-149 and MDA-MB-436 cell
lines. A recent report revealed that upregulation of AKT3 conferred resistance to
MK2206 (Stottrup et al., 2016). In line with this study, our results revealed that the
SUM-149 and MDA-MB-436 cell lines displayed the highest gene and protein level
expression of AKT3 in the cohort of cell lines used in this study (Figure 3.3);
moreover, our results demonstrated that AKT3-specific phosphorylation was
resistant to MK2206 compared to AKT1 phosphorylation.

Further, our data

indicate that AKT3 expression, at least in the SUM-149 cell line, conferred
resistance to pan-class I PI3’Kinase inhibition and pan-mTOR inhibition (Figure
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3.5B).

This result was intriguing because numerous reports have implicated

elevated expression and activity of AKT3 in the tumorigenesis and progression of
melanoma, glioblastoma and triple negative breast cancer (Chin et al., 2014; Stahl
et al., 2004; Turner et al., 2015), and these cancers are often associated with
decreased (or loss of) PTEN expression (Madhunapantula and Robertson, 2009).
A limitation to these studies was the modulation of AKT3 activity by RNA
interference to reduce AKT3 levels or restoration of PTEN protein using expression
vectors. While these methods were critical for understanding the contribution of
AKT3 and PTEN loss in these diseases, these methods are not clinically
applicable. Various microRNAs (miRNA) have been identified as regulators of
AKT3 expression in many cancers including thyroid, ovarian and triple negative
breast cancer and have been identified as potential therapeutic targets for patients
with these diseases, however, preclinical studies and phase I clinical trials are still
being done to determine the potential of miRNA as therapeutic strategies
(Christopher et al., 2016; Li et al., 2017; Ma et al., 2015).
To explore the mechanism of AKT3 activation, immunoprecipitation and
immunoblot analysis of AKT1 and AKT3 were performed revealing that these two
AKT isoforms are differentially regulated (Figure 3.6). Inhibition of pan-class I
PI3'Kinases was sufficient to prevent AKT1 activation, but only partially inhibited
AKT3 activation. Further, the data indicated that inhibition of mTOR was also
sufficient to inhibit AKT1 activation but not AKT3 activation. However, inhibition of
AKT3 activation was achieved by non-specific pan-class PI3'Kinase inhibition with
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Wortmannin. This result is consistent with studies showing that AKT
phosphorylation is not only regulated by PtdIns(3,4,5)P3 (canonical PI3’Kinase
signaling) but also by PtdIns(3,4)P2 (Franke et al., 1997b; Scheid et al., 2002; Vara
et al., 2004). Class I PI3’Kinases are primarily recognized for their ability to
produce PtdIns(3,4,5)P3 (Liu et al., 2009; Zhao and Vogt, 2008); however, class I
PI3’Kinases also contribute to the formation of PtdIns(3,4)P2 which are also
produced by class II PI3’Kinases (See Figure 1.6 & Figure 4.1) (Engelman et al.,
2006).

Therefore, if AKT activation is regulated by PtdIns(3,4,5)P2 and

PtdIns(3,4)P2, which can be generated by both class I and class II PI3’Kinases,
then it can be concluded that pan-class I PI3’Kinase inhibition would not be
sufficient to block PtdIns(3,4)P2-mediated AKT activation.

Because class I

PI3’Kinase inhibition sufficiently inhibits AKT1 activation while pan-class
PI3’Kinase inhibition is required to inhibit AKT3 activation, we can hypothesize that
AKT1 preferentially binds PIP3, while AKT3 binds PIP3 and PtdIns(3,4)P2.
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Figure 4.1: Kegg Pathway emphasizing class I and class II PI3’Kinase
mediated production of PtdIns(3,4,5)P3 and PtdIns(3,4)P2

Figure 4.1: Partial Kegg Pathway of the Phosphatidylinositol Signaling system with emphasis on
PI3’Kinase mediated production of phosphatidylinositol species. The canonical function of class I
PI3’Kinase (red pathway) catalytic enzymes is the production of PtdIns(3,4,5)P3 (solid red circle)
from PtdIns(4,5)P2. PtdIns(3,4,5)P3 is a lipid second messenger which serves as a docking site
for PDK1 and AKT, subsequently leading to AKT activation (yellow rectangle). AKT activation
can also occur by the interaction between AKT and PtdIns(3,4)P2 (red and blue dashed oval).
class I (red pathway) and class II (blue pathway) contribute to the formation of PtdIns(3,4)P2,
indicating that class I and II PI3’Kinases mediate AKT activation. Inhibition of class I PI3’Kinase
enzymatic activity alone would be insufficient to inhibit PtdIns(3,4)P2 mediated activation of AKT.
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Because wortmannin is a non-specific PI3'Kinase inhibitor with numerous
off-target effects, we utilized the pan-class PI3'Kinase inhibitor, GDC0032, due to
its high specificity for PI3'Kinases and lack of known off-target effects (see Table
1). Our data revealed that AKT3 phosphorylation in the SUM-149 cell line was
resistant to GDC0032, but that when the treatment concentration was increased
to 3 µM, GDC0032 was able to inhibit AKT3 phosphorylation (Figure 3.8). This
result is significant, because GDC0032 has enzymatic activity against the PI3KC2β isoform at higher concentrations than the class I PI3’Kinases (see Table 1).
The ability of GDC0032 to inhibit AKT3 activity at increased concentrations given
the context of its specificity suggests that class I PI3'Kinases and PI3K-C2β cooperate to regulate the activation of AKT3 and provides a contextual basis for our
conclusion that AKT3 is non-canonically regulated by both class I and class II
PI3’Kinase activity.
Interestingly, AKT3 and PIK3C2B (PI3K-C2β) both lie on the long arm of
chromosome 1 (1q43-q44 and 1q32.1, respectively). While the 1q43-q44 and 1q32
region are not considered a functional unit, amplification of these regions are
commonly associated with breast cancer (Orsetti et al., 2006). Moreover, a recent
study identified AKT3 and PIK3C2B as a part of a quartet of phosphatidylinositol
signaling molecules that localize to 1q and suggested that these molecules may
co-operate to regulate PI3’Kinase signaling in a subset of breast cancers (Waugh,
2014).

Further, data mining of cBioPortal revealed that AKT3 is the most

commonly amplified AKT isoform (Figure 4.2A) and identified PIK3C2B as the
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most commonly amplified PI3’Kinase isoform (Figure 4.2B) in breast carcinomas.
In conjunction with the hypothesis that AKT3 and PIK3C2B are functionally related
(Orsetti et al., 2006; Waugh, 2014), querying the expression of AKT3 and PIK3C2B
in breast carcinomas within the cBioPortal database revealed that AKT3 and
PIK3C2B are significantly co-expressed and co-amplified (Figure 4.2C).
Taken together with our data, this supports our conclusion that AKT3 may
indeed be specifically associating with the PI3K-C2β-produced PtdIns(3,4)P2.
Future studies aimed at elucidating the specific phosphatidylinositols that
associate with AKT1 and AKT3 would identify whether differential lipid binding
exists between the AKT1 and AKT3 isoforms.
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Figure 4.2: Oncoprint Analysis of genomic alterations in breast carcinomas

Figure 4.2: Oncoprint Analysis of AKT1, AKT2 and AKT3 genomic alterations in breast
carcinomas. The cBioPortal database was queried for genomic alterations of AKT1, AKT2 and
AKT3 in all breast carcinoma samples (4462 total patients’ sample) available. Amplifications,
deep deletions and mutations are identified by the colors indicated in the key (D) below the
analysis. A) Genomic alterations of AKT1, AKT2 and AKT3. Analysis reveals that the AKT1
isoform is the most mutated of the AKT isoforms within this analysis. AKT3 is the most amplified
of the AKT isoforms in this analysis. B) Genomic alteration of the class I, II and III PI3’Kinase
catalytic isoforms. Class I PI3Ka is the most mutated PI3’Kinase catalytic isoform. PIK3C2B is the
most amplified PI3’Kinase catalytic enzyme. C) Comparison of genetic alteration of PIK3C2B and
AKT3 in the queried database. PIK3C2B and AKT3 are frequently significantly co-expressed. D)
Key of genetic alterations.
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Unfortunately, AKT3 and class II PI3’Kinase specific inhibitors have not yet
been developed. Due to their limited range of inhibition, the development and
application of AKT3 and class II PI3’Kinase specific inhibitors in a clinical setting
could result in decreased toxic side-effects compared to the broad-spectrum AKT
and pan-class I PI3’Kinase inhibitors currently utilized in clinical trials. One of the
methods used in our study to explore the role of PI3’Kinase/AKT pathway
activation in our cells was the assessment of treatment effectiveness by clonogenic
assay. Clonogenic assay is the method of choice to measure cell reproductive
death after treatment and to determine the effectiveness of cytotoxic agents. We
show that pan-class PI3’Kinase inhibition by GDC0032, at a concentration
sufficient to reduce both AKT1 and AKT3 phosphorylation dramatically reduces (5fold) the clonogenicity of the SUM-149 cell line. Interestingly, combining GDC0032
with gefitinib, an EGFR inhibitor, resulted in an even greater (17-fold) reduction of
clonogenicity (Figure 3.17). This data is consistent with studies that have shown
that inhibition of EGFR and PI3’Kinases may be a beneficial therapeutic treatment
strategy for patients expressing EGFR and loss of PTEN (Li et al., 2012; She et
al., 2016; Tao et al., 2014; Yi et al., 2013).
Preliminary studies, in our laboratory, investigating the functional
significance of inhibiting AKT3 phosphorylation, without inhibiting PI3’Kinase
activity, were done using clonogenic assays (Figure 4.3). We found that inhibition
of AKT3 phosphorylation, with 5 µM of MK2206, failed to inhibit clonogenicity;
strikingly, combining 5 µM MK2206 with 1 µM Gefitinib resulted in a dramatic
131

reduction of the clonogenic potential of the SUM-149 cell line (Figure 4.3A). Taken
together, this data indicates that inhibition of AKT3 phosphorylation is not sufficient
to irreversibly inhibit the growth of the SUM-149 cell line. However, the data does
indicate that the inhibition of AKT3 phosphorylation is necessary for EGFR
inhibition to impact clonogenicity. The data in Figure 4.3A reveals that gefitinib in
combination with 1 mM or 3 mM MK2206 did not markedly affect the clonogenic
potential of the SUM-149 cell line. Only when 1µM gefitinib was combined with 5
mM MK2206, was clonogenicity a 7-fold reduction in the clonogenic potential of
the SUM-149 cell line observed. Taken together, this data indicates that elevated
AKT3 is a biomarker of resistance to not only PI3’Kinase pathway inhibition but
also EGFR inhibition.

These data also suggest that while AKT3 activity is

important, inhibition of PI3’Kinase activity or inhibition of EGFR activity is needed
in AKT3 positive PTEN-null basal breast cancer cell lines.
Re-expression of PTEN in the panel of PTEN-null basal breast cancer cell
lines, failed to inhibit the elevated levels of AKT phosphorylation observed in these
cells. Instead, PTEN re-expression led to variable reductions of AKT
phosphorylation across the panel of basal-like breast cancer cell lines, which
indicated that the constitutive PI3’Kinase/AKT pathway activation observed in
basal breast cancers is not solely driven by PTEN loss (Figure 3.18). This result
was unexpected because loss of PTEN expression is commonly associated with
deregulation of the PI3’Kinase signaling cascade in basal breast cancer (Marty et
al., 2008; Saal et al., 2007; Vazquez and Sellers, 2000).
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In this dissertation, we went on to show that restoration of PTEN in the SUM149 and MDA-MB-436 cell lines sensitized AKT phosphorylation to class I
PI3’Kinase inhibition (BKM120), allosteric AKT inhibition (MK2206), and mTOR
inhibition (KU0063794) (Figure 3.19). This data suggests that re-expression of
PTEN in basal breast cancer cell lines results in the restoration of canonical
PI3’Kinase signaling. Preliminary data, utilizing PTEN re-expressing SUM-149 cell
line revealed that PTEN re-expression slightly reduced the clonogenic potential of
the SUM-149 cell line (Figure 4.3B), however, inhibition of EGFR (1 mM Gef) in
conjunction with PTEN re-expression resulted in a 4-fold reduction in the
clonogenic potential of the SUM-149 cell line. This data validates studies that
identify dual inhibition of PI3’Kinase activity in conjunction with inhibition of EGFR
as a potential therapeutic strategy for patients presenting with PTEN-null, EGFR+
basal breast cancer (Li et al., 2012; Martin et al., 2012; She et al., 2016; Tao et al.,
2014; Yi et al., 2013).
The data in Figure 4.3C is the graphical representation of Figure 4.3A
combined with Figure 4.3B; by visualizing the data in this manner, PTEN reexpression combined with EGFR inhibition elicits the same effect as inhibiting
AKT3 phosphorylation with 5 mM MK2206 combined with EGFR inhibition. If our
hypothesis, that inhibiting AKT3 phosphorylation is necessary but not sufficient to
reduce clonogenicity, is correct than it can be hypothesized that PTEN reexpression coupled with EGFR inhibition would result in a reduction of AKT3
phosphorylation.
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Figure 4.3: Reduction of the clonogenic potential of SUM-149 cells

Figure 4.3 SUM-149 cells were seeded (1x103) per well and treated according to directions in
Methods section. A) SUM-149 cells treated with 1 µM, 3 µM, 5 µM of MK2206 alone or in
combination with 1 µM gefitinib. B) LacZ or PTEN expressing SUM-149 cells treated with 0.01%
DMSO or 1 µM gefitinib. C) Graphical representation of A) and B). Error bars represent the range
of the data of three replicates.
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Preliminary studies, assessing the response of AKT1 and AKT3 activation
in the presence of PTEN re-expression alone and in combination with EGFR
inhibition have been done in the SUM-149 cell line (Figure 4.4A). For these
experiments, SUM-149 LacZ-overexpressing and SUM-149 PTEN re-expressing
cells were treated with 1µM Gefitinib for 24 hr and 48 hr. Following treatment, cells
were lysed and immunoprecipitated for AKT1 and AKT3 and immunoblotted for
phospho-AKT. As shown in Figure 4.4A, a reduction of AKT1 phosphorylation was
observed at 48 hrs of treatment with gefitinib in the SUM149 control cells.
Considering that 1 µM Gefitinib failed to reduce AKT1 and AKT3 phosphorylation
in the SUM-149, MDA-MB-436 and HCC-1937 cell lines after a 2 hr treatment
(Figure 3.6), it was not surprising that a longer treatment of gefitinib was needed
to affect AKT1 phosphorylation in the control cells (Figure 4.4A).
This result is significant because it suggests that despite expression of
EGFR, EGFR activity is deregulated and uncoupled in PTEN-null EGFR+ basal
breast cancer cells, validating previous studies from our laboratory (Kappler et al.,
2015). Furthermore, EGFR expression is present and/or overexpressed in 80% of
basal breast cancer samples, is significantly correlated with elevated PI3’Kinase
pathway activation, and has been implicated as a potential molecular target for the
treatment of patients with basal breast cancer (Burness et al., 2010; Cheang et al.,
2008; Corkery et al., 2009; Martin et al., 2012; Park et al., 2014; She et al., 2016).
Despite the clear association of EGFR signaling in the poor prognosis of patients
presenting with this molecular phenotype, clinical trials have failed to identify
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efficacy of EGFR inhibitors for the treatment of breast cancer indicating that the
current understanding of EGFR signaling is incomplete (Baselga et al., 2005;
Comis, 2005; Smith et al., 2007; von Minckwitz et al., 2005). The data presented
in Figure 4.4A, offers insight into the failure of EGFR inhibitors in clinical trials.
Immunoprecipitation of AKT3 revealed that AKT3 phosphorylation was
more resistant to EGFR inhibition, evident by the lack of response of AKT3
phosphorylation to gefitinib, even at 48hr. We can conclude that AKT3 activity,
compared to AKT1 activity, is resistant to EGFR inhibition. Taken together, this
data offers insight into the resistance of patients to EGFR inhibition in the clinical
setting. Patients with expression of AKT3 would not demonstrate a favorable
response to EGFR inhibitors due to the resistance of AKT3 activity to gefitinib.
This conclusion is validated by the failure of gefitinib to reduce the clonogenic
potential of the SUM-149 cell line (Figure 4.3).
Interestingly, re-expression of PTEN alone, was capable of dramatically
reducing of AKT1 phosphorylation compared to control untreated cells. Based
upon this result, we can conclude that PTEN is operating canonically and that
PTEN re-expression is capable of reversing the canonical PI3’Kinase mediated
activation of AKT1 (Figure 4.4A). Combining PTEN re-expression with EGFR
inhibition completely inhibited AKT1 phosphorylation at 24 hr, suggesting that
PTEN re-expression results in the recoupling of EGFR activity to AKT1 activation.
Conversely, PTEN re-expression resulted in a marginal reduction of AKT3 specific
phosphorylation. If PTEN is canonically regulating class I PI3’Kinase enzymatic
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activity, then we can determine that our previous observation, that canonical
PI3’Kinase signaling partially regulates AKT3 activity and that inhibition of
canonical PI3’Kinase signaling alone is insufficient to dramatically reduce AKT3
activity, is correct.
Strikingly, AKT3 phosphorylation was dramatically reduced in the SUM-149
PTEN re-expressing cells treated with 24 hr and 48 hr of gefitinib. The result was
further evident in the whole cell lysate analysis (Figure 4.4A); PTEN re-expression
and EGFR inhibition reduced total AKT phosphorylation indicating that PTEN reexpression recouples EGFR to AKT activity. Taken together with the colony
forming data in Figure 4.3 we confirmed our hypothesis that PTEN re-expression
coupled with EGFR inhibition results in a dramatic reduction of AKT3
phosphorylation.
It has been previously reported that AKT3 and PTEN are commonly
regulated in many cancer types (Li et al., 2017; Ma et al., 2015; Wang et al., 2011;
Zhang et al., 2013). To determine if PTEN re-expression regulated the expression
of AKT3, we compared the protein expression of AKT3 in SUM-149 PTEN reexpressing cells to LacZ control cells by western blot analysis. We did not see a
change in the expression of AKT3 between the two conditions, indicating that
PTEN contributes to the regulation of AKT activity but not AKT expression.
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Figure 4.4 Re-expression of PTEN in the SUM-149 cell line in combination
with EGFR inhibition blocks AKT3 phosphorylation

Figure 4.4 A) SUM-149 LacZ and SUM-149 PTEN re-expressing cells were treated with 1 mM
gefitinib for 24 or 48 hr, cells were lysed and immunoprecipitated for AKT1 and AKT3 using
Protein A/G beads (resulting in doublet in immunoblot band) and then immunoblotted for
phospho-AKT and Total-AKT levels. Immunoprecipitation, of AKT1 and AKT3 in these
experiments were done using Protein A/G beads (all other immunoprecipitation experiments were
done utilizing Protein A beads. Protein A beads are less effective at purifying antibodies from
protein/antibody mixture, however, Protein A beads do not result in non-specific banding in
western blot analysis. Therefore, because the data in this experiment was performed utilizing
Protein A/G beads, a non-specific band is present in the phospho-AKT immunoblot. The black
arrow denotes the phospho-AKT band. Whole cell lysis is included as control. B) Expression of
AKT3 in SUM-149 LacZ and SUM-149 PTEN expressing cells.
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Chapter 5:
Unanswered Questions and Future Directions
The data presented this study has identified that AKT1 activation is
governed by canonical PI3’Kinase pathway signaling and indicated that the
mTORC2 complex phosphorylates AKT1 at the Ser473 site. We further identified
that AKT3 is regulated non-canonically and our data indicated that another kinase,
other than mTORC2, is operating as PDK2 for AKT3. Preliminary work in our lab
revealed that shRNA mediated knockdown of ILK, failed to inhibit AKT3
phosphorylation in the SUM-149 cell line (data not shown), suggesting that
reduction of ILK was not sufficient to affect AKT3 activation. Future studies using
shRNA mediated ILK knockdown in conjunction with mTOR inhibition must be
done to determine if ILK is cooperating with mTORC2 complex to phosphorylate
AKT3 at the Ser472 site. Because RNA interference, shRNA, fails to completely
ablate gene function, CRISPR/Cas9 mediated gene knockout may be needed to
fully understand the contribution of ILK on AKT3 phosphorylation. If knockout of
ILK, in conjunction with mTOR inhibition fails to inhibit AKT3 phosphorylation, it
could be concluded that ILK is not acting as the PDK2 in the SUM-149 cell line.
Therefore, other candidates such as DNA-PK, Protein kinase C beta II (PKCβII),
MAP kinase-activated protein kinase 2 (MAPKAP2) and other kinases must be
considered as potential PDK2 molecules in the SUM-149, MDA-MB-436 and HCC1937 cell lines (Lee et al., 2013; Wang et al., 2008).
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The work presented in this study indicates the AKT1 activation is regulated
by canonical PI3’Kinase signaling while AKT3 activation is regulated by a noncanonical signaling pathway, in which, PI3K-C2β, is mediating AKT3 activity. In
the present study, we utilized GDC0032, which inhibits PI3K-C2β activity at and
IC50 of 292 nM which is about 32-fold higher than the inhibitory concentration of
GCD0032 for the class I PI3’Kinase enzymes. Therefore, higher concentration of
GCD0032 was needed to inhibit PI3K-C2β mediated AKT3 activation. However,
despite the clear connection that non-canonical PI3’Kinase activity is regulating
AKT3 activity, further work is needed to determine specifically how PI3K-C2β is
contributing to the signaling network of PTEN-null, AKT3+ basal breast cancer
cells. To begin to understand the contribution PI3K-C2b alone in this context,
preliminary studies utilizing shRNA mediated knockdown of PIK3C2B were done
in the SUM-149 cell line (data not shown). Knockdown of PIK3C2B alone was
insufficient to inhibit total AKT phosphorylation; because shRNA mediated
reduction of gene expression is not complete, residual PI3K-C2β expression may
be contributing to the failure of PI3K-C2β to reduce AKT phosphorylation. Future
studies, utilizing CRISPR/Cas9 mediated knockout of PIK3C2B need to be done
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in order assess how loss of PI3K-C2β expression affects AKT/AKT3
phosphorylation.

There are seven different species of phosphatidylinositides (PtdIns) that are
found in the cell, each containing different structures and different charges
(Stahelin et al., 2014), therefore future studies, identifying the repertoire of the
phosphatidylinositol species would offer insight to the complex nature of the
PI3’Kinase signaling cascade. PtdIns(3,4,5)P3 and PtdIns(3,4)P2 have both been
implicated in the regulation of AKT activity. Studies have identified PtdIns(3,4)P2
as the major contributor to AKT activation but also recognize that PtdIns(3,4,5)P3
is required for AKT activation (Scheid et al., 2002). Measuring the levels of the
different PtdIns in steady-state levels and upon treatment with the inhibitors utilized
in this study, would identify how the distribution of the PtdIns species change in
response to PI3’Kinase pathway inhibition. Coupled with the response of AKT
phosphorylation in the same conditions would result in a robust data analysis which
would indicate the interplay in the PtdIns species and their involvement in the
activation of AKT. By measuring the changes in the PtdIns species in the presence
of PTEN re-expression, the specific lipid products for PTEN could be assessed;
canonically PTEN is a 3’phosphatase which dephosphorylates PtdIns(3,4,5)P3
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creating PtdIns(4,5)P2, measuring the PIP species in the presence of PTEN would
also identify if PTEN is dephosphorylating the PtdIns(3,4)P2 to produce PtdIns(4)P.
Briefly, PtdIns measure can occur by radiolabeling activated PtdIns with [32P]Pi,
extracting the cellular lipids, and separating them by high-performance liquid
chromatography (HPLC) (Stahelin et al., 2014). A caveat to this method is the time
intensive and cost effect nature of this assay, however, the implications that the
data gathered by performing these future studies would provide invaluable insight
in the differential regulation of AKT1 and AKT3 activity with specific awareness to
the contribution that the repertoire of PtdIns has in the regulation of AKT1 and
AKT3 activation.

GDC0032, is a pan class PI3’Kinase inhibitor that specially targets the class
II catalytic enzyme, PI3K-C2β. This study identified that GDC0032 is capable of
inhibiting AKT3 phosphorylation (Figure 3.8) in the SUM-149 (Figure 3.14), MDAMB-436 (Figure 3.15), and the HCC-1937 (Figure 3.16) cell lines. However, due
to the 32-fold higher inhibitor concentration of GDC0032 for PI3K-C2β, compared
to the class I PI3’Kinases, GDC0032 (although currently available for clinical trials)
would not be a good candidate to treat patients with elevated AKT3 expression,
because a higher concentration of drug is to inhibit PI3K-C2β enzymatic activity
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(Lopez et al., 2014). There are currently no specific PI3K-C2β inhibitors available
(Mountford et al., 2015), despite the clear importance of the enzyme in cancer
(Orsetti et al., 2006; Stange et al., 2006; Traer et al., 2006; Waugh, 2014). Taken
together with the data presented in this study, there is a clear need for the
development of class II, specifically PI3K-C2β, inhibitors.

A future direction designed based upon the data presented in this study
should be focused on identifying drugs that specifically inhibit PI3K-C2β. Drug
discovery is often impeded by the target selection process (Hughes et al., 2011;
Knowles and Gromo, 2003), in which a candidate protein is identified, the data
present in this study along with others, has identified PI3K-C2β as a valid target
(Traer et al., 2006; Waugh, 2014). Future studies can be performed using high
content screening (HCS) in a two-dimensional (2D) cell culture model in which cells
can be plated in a 96, 384 or 1536 well plate format (depending on how many
candidate drugs will be used), and IHC can be used to detect phosphorylated
protein expression as a readout of drug efficiency. The SUM-149 cell line would
be a perfect model cell line in the identification of effectiveness of drug inhibition
for PI3K-C2β, due to the high-level of AKT3 phosphorylation in these cells, offers
a unique opportunity to identify a new drug while also knowing that it is functional
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in vitro which is significant because many drugs fail to progress in the drug
discovery pipeline due to lack of activity in complex biological systems (Knowles
and Gromo, 2003).
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Chapter 6:
Conclusion
A subset of basal breast cancers is characterized by inactivating p53
mutations, loss of PTEN expression and over-expression of EGFR. In this study,
we report that a subset of basal-like breast cancer cell lines also has overexpression of AKT3 which contributes to the intrinsic resistance of these cells to
inhibition of key PI3’Kinase pathway mediators. Over-expression of AKT3 and loss
of PTEN has not only been identified as mediators of tumorigenesis in basal-like
breast cancer but has been implicated in other cancers such as melanoma and
glioblastoma. The work presented in this dissertation, to our knowledge, is the first
study to elucidate that activation of AKT1 and AKT3 is differentially regulated by
class I and class II PI3’Kianses (Figure 5.1). These findings emphasize the need
for further investigation into the regulation of these two isoforms in the
pathogenesis of breast cancer. Further studies should be done to determine if the
differential regulation of AKT1 and AKT3 seen in PTEN-null basal breast cancers
also exists in other cancers harboring elevated AKT3 expression and loss of PTEN
such as melanoma and glioblastoma.
In conclusion, PI3’Kinase signaling in PTEN-null basal breast cancers is
complex, multifaceted and requires the development of specific targeted inhibitors
in order to effectively inhibit the drivers of signaling in this subtype of breast cancer.
Future studies including basal breast cancer cell lines and basal breast cancer
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patient samples should consider the presence of non-canonical PI3’Kinase
signaling in order to effectively identify therapeutic strategies that will have a low
toxicity index, progress past phase II and phase III clinical trials, and ultimately
lead to FDA approved targeted strategies for the treatment of patients with basal
breast cancer.
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Figure 5.1 Schematic summarizing data presented in dissertation

Figure 5.1. PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are lipid second messengers that serve as docking
sites for AKT. The class I PI3’Kinase enzymes function by phosphorylating the 3’-OH group within
the inositol rings of phosphatidylinositols to produce PtdIns(3,4,5)P3 and PtdIns(3,4)P2. Canonical
PI3’Kinase signaling suggests that AKT activation is solely by class I PI3’Kinase production of
PtdIns(3,4,5)P3. However, it is known that PtdIns(3,4,)P2 serves as a potent activator of AKT
phosphorylation. The data presented in this dissertation reveals that AKT1 and AKT3 are
differentially regulated in PTEN-null basal-like breast cancer cell lines. Our data indicates that AKT1
is regulated by conical PI3’Kinase signaling and is phosphorylated at the Ser473 site by mTORC2.
In contrast, AKT3 is regulated by a non-canonical PI3’Kinase signaling mechanism in which class
I PI3’Kinases and the class II PI3K-C2β isoform is regulating the activation of AKT3. Our data also
indicated that the mTORC2 complex is partially acting as the PDK2 for AKT3, however, the failure
of mTOR inhibition to inhibit AKT3 phosphorylation at the Ser473 site, suggests that another kinase
is cooperating with mTORC2 as the PDK2 for AKT3.
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